Hemodialysis Novel Therapies Consortium  Clinical Research Protocol  
CONFIDENTIAL  
Do not disclose or use except as authorized by the Hemodialysis Novel Therapies Consortium.   
 
 
Gut Microbiome and p- Inulin in Hemodialysis  
 
 
 A multi -center study to characterize the gut microbiome of individuals 
with  end- stage renal disease treated with maintenance hemodialysis, 
and to explore effects of p -inulin on the gut microbiome  
  
Funding Sponsor:  National Institutes of Diabetes and Digestive  
and Kidney Diseases  
National Institutes of Health  
2 Democracy Plaza  
6707 Democracy Boulevard  
Bethesda, MD  20892 -5458 
 
Protocol Number:  NA 
 
 
   
Initial version:  V1.0, July 1 , 2015   
Amended:  V2.0, September 9, 2015  
Amended:  [date]  
 
HD Microbiome Study   Page i 
Version  V2.0, September 9, 2015  
CONFIDENTIAL  
Do not disclose or use except as authorized by the Hemodialysis Novel Therapies Consortium.  Table of Contents  
 
LIST OF ABBREVIATION S ................................................................................................................... IV 
STUDY SUMMAR Y ............................................................................................................................. V  
1 INTRODUCTION  .........................................................................................................................1  
1.1 B ACKGROUND  ................................................................................................................................. 1  
1.2 S TUDY AGEN T .................................................................................................................................. 2  
1.3 C LINICAL DATA ON PREBIOTICS AND P -INULIN  ....................................................................................... 3  
1.4 D OSE RATIONALE AND RISK/BENEFITS  ................................................................................................. 4  
1.4.1  Risks  ......................................................................................................................................... 5  
2 STUDY OBJECTIVES  .....................................................................................................................5  
2.1 P RIMARY OBJECTIVES  ....................................................................................................................... 5  
2.2 S ECONDARY OBJECTIVES  ................................................................................................................... 5  
3 STUDY DESIGN  ...........................................................................................................................6  
3.1 G ENERAL DESIGN  ............................................................................................................................. 6  
3.2 S TUDY ENDPOINTS  ........................................................................................................................... 6  
3.2.1  Primary Endpoints  ................................................................................................................... 6  
3.2.2  Secondary Endpoints  ............................................................................................................... 6  
4 PARTICIPANT SELECTIO N AND WITHDRAWAL  .............................................................................7  
4.1 I NCLUSION CRITERIA  ......................................................................................................................... 7  
4.2 E XCLUSION CRITERIA ......................................................................................................................... 7  
4.2.1  Women of Childbearing Potential  ........................................................................................... 8  
4.3 R ECRUITMENT  ................................................................................................................................. 8  
4.4 E ARLY WITHDRAWAL OF PARTICIPANTS AND EARLY STUDY TERMINATION  ................................................. 9  
4.4.1  Early Withdrawal of Participants  ............................................................................................  9 
4.4.2  Dose Reduction and Discontinuation of p-Inulin ..................................................................... 9  
5 STUDY PROCEDURES  ..................................................................................................................9  
5.1 S TUDY VISIT SCHEDULE  ..................................................................................................................... 9  
5.1.1  Pre-screening Activities  ......................................................................................................... 10 
5.1.2  Screening/Baseline Visit  ........................................................................................................ 10 
5.1.3  Week 4, 8, 12, 16, 20, 24, and 28 Visits and Weekly Telephone Contacts  ............................ 10 
5.2 B IOSAMPLE COLLECTION PROCEDURES AND SCHEDULE  ......................................................................... 12 
5.2.1  Weeks 1 -7 .............................................................................................................................. 13 
5.2.2  Weeks 8-9 .............................................................................................................................. 13 
5.2.3  Weeks 10 -18 .......................................................................................................................... 13 
5.2.4  Weeks 19 -20 .......................................................................................................................... 13 
5.2.5  Weeks 21 -28 .......................................................................................................................... 13 
5.3 S TOOL AND BLOOD ANALYSES  .......................................................................................................... 13 
5.3.1  Metabolites and Inflammatory Markers.  .............................................................................. 13 
6 STUDY AGENT  .......................................................................................................................... 15 
6.1 D ESCRIPTION  ................................................................................................................................. 15 
6.2 T REATMEN T REGIMEN  .................................................................................................................... 15 
6.3 A DMINISTRATION OF STUDY AGENT  .................................................................................................. 16 
HD Microbiome Study   Page ii 
Version  V2.0, September 9, 2015  
CONFIDENTIAL  
Do not disclose or use except as authorized by the Hemodialysis Novel Therapies Consortium.  6.4 R ECEIVING , STORING , DISPENSING AND RETURNING STUDY AGENT  ........................................................ 16 
6.4.1  Receiving Study Product (p- Inulin) Supplies  .......................................................................... 16 
6.4.2  Storage  .................................................................................................................................. 16 
6.4.3  Dispensing Study Agent  ......................................................................................................... 16 
6.4.4  Return or Destruction of Study Agent  ................................................................................... 16 
6.5 P ARTICIPANT ADHERENCE MONITORING  ............................................................................................ 17 
6.6 C ONCOMITANT THERAPY  ................................................................................................................. 17 
7 STATISTICAL PLAN  .................................................................................................................... 17 
7.1 S AMPLE  SIZE DETERMINATION  ......................................................................................................... 17 
7.2 M ISSING DATA .............................................................................................................................. 19 
7.3 S TATISTICAL METHODS  ................................................................................................................... 19 
7.3.1  Sequence Data Processing..................................................................................................... 19 
7.3.2  Analysis of Microbial Composition ........................................................................................ 20 
7.3.3  Analysis of metabolomic profile and targeted metabolites .................................................. 21 
7.3.4  Association between microbiome composition and metabolites .......................................... 21 
7.3.5  Analysis of Safety  .................................................................................................................. 21 
8 SAFETY AND ADVERSE EVENTS  ................................................................................................. 21 
8.1 D EFINITIONS  .................................................................................................................................. 21 
8.1.1  Adverse Event  ........................................................................................................................ 22 
8.1.2  Serious Adverse Event  ........................................................................................................... 22 
8.1.3  Unanticipated Problems Involving Risk to Participants or Others  ........................................ 22 
8.1.4  Pre-Existing Condition  ........................................................................................................... 22 
8.2 A DVERSE EVENT REPORTING PERIOD  ................................................................................................. 22 
8.2.1  Post -st udy Adverse Event  ...................................................................................................... 23 
8.3 R ECORDING OF ADVERSE EVENTS  ...................................................................................................... 23 
8.3.1  Anticipated Adverse Events  ................................................................................................... 23 
8.4 R EPORTING OF SERIOUS ADVERSE EVENTS AND UNANTICIPATED PROBLEMS  ............................................ 24 
8.4.1  Investigator Reporting to the IRB  .......................................................................................... 25 
8.4.2  DCC Notification to Participating Investigators  .................................................................... 25 
8.5 M EDICAL MONITORING  .................................................................................................................. 26 
8.5.1  Independent Data and Safety Monitoring B oard (DSMB)  ..................................................... 26 
9 DATA MANAGEMENT  ............................................................................................................... 26 
9.1 D ATA QUALITY  .............................................................................................................................. 27 
9.1.1  Qualit y Control Activities  ....................................................................................................... 27 
9.1.2  Routine reports  ...................................................................................................................... 27 
9.2 D ATA SECURITY  ............................................................................................................................. 27 
9.2.1  Confidentiality ....................................................................................................................... 28 
9.3 S OURCE DOCUMENTS  ..................................................................................................................... 28 
9.3.1  Case Report Forms  ................................................................................................................ 28 
9.3.2 Maintaining Anonymity of Submitted Medical Records  ....................................................... 29 
9.3.3  Data Sharing .......................................................................................................................... 29 
9.3.4  Records Retention  ................................................................................................................. 29 
10 STUDY MONITORING, AU DITING, AND INSPECTI NG .................................................................. 29 
10.1  S TUDY MONITORING PLAN .............................................................................................................. 29 
10.2  A UDITING AND INSPECTING  .............................................................................................................. 29 
HD Microbiome Study   Page iii 
Version  V2.0, September 9, 2015  
CONFIDENTIAL  
Do not disclose or use except as authorized by the Hemodialysis Novel Therapies Consortium.  11 ETHICAL CONSIDERATIO NS ....................................................................................................... 30 
12 STUDY FINANCES  ..................................................................................................................... 30 
12.1  F UNDING SOURCE  .......................................................................................................................... 30 
12.2  C ONFLICT OF INTEREST  .................................................................................................................... 30 
12.3  P ARTICIPANT STIPENDS OR PAYMENTS  ............................................................................................... 30 
13 PUBLICATION PLAN  .................................................................................................................. 30 
14 REFERENCES  ............................................................................................................................ 32 
15 ATTACHMENTS  ........................................................................................................................ 36 
15.1  S TUDY PROCEDURES  ....................................................................................................................... 37 
15.2  DSMB  CHARTER  ............................................................................................................................ 38 
 
HD Microbiome Study   Page iv 
Version  V2.0, September 9, 2015  
CONFIDENTIAL  
Do not disclose or use except as authorized by the Hemodialysis Novel Therapies Consortium.  List of Abbreviations  
AE adverse event 
CKD chronic kidney disease  
CRF case report form  
CVD  cardiovascular disease  
DCC D ata Coordinating Center  
DMS  data management system  
DSMB  D ata and Safety Monitoring Board  
ESRD  end stage renal disease  
FOS fructo -oligosaccharides  
FTP File Transfer Protocol  
HD hemodialysis  
HIPAA  H ealth Insurance Portability and A ccounting Act 
IDS I nvestigational Drug Service  
IRB I nstitutional Review Board  
MOP  M anual of P rocedures  
NIDDK  National Institute of Diabetes and Digestive and Kidney Diseases  
NIH National Institutes of Health 
OHRP  Office of Human Research Protection s 
OTU  operational taxonomic unit  
PHI protected health information  
SAE serious adverse event  
SAP statistical analysis plan  
UAE  unanticipated adverse even t 
 
 
HD Microbiome Study   Page v 
Version  V2.0, September 9, 2015  
 
CONFIDENTIAL  
Do not disclose or use except as authorized by the Hemodialysis Novel Therapies Consortium.  Study Summary  
Title  Gut Microbiome and p- Inulin in Hemodialysis  
Short Title  Gut Microbiome in HD 
Protocol Number   NA 
Phase  Phase I 
Methodology  Non-randomized, open label, 3- period  crossover trial , with repeated measures within 
period  
Study Duration  28 weeks for participant; 15 months  for full study (projected)  
Study Center(s)  Brigham and Women’s Hospital  
George Washington University  
University of Washington  
Vanderbilt  University  
University of Pennsylvania (Data Coordinating Center)  
Objectives  • To evaluate intra - and inter -participant  variability in the composition and metabolic 
products  of the gut microbiome  
• To evaluate the tolerability and short -term safety of p-inulin  
• To assess the feasibility of sample collection in this populatio n  
Number of Participants  Up to 20 individuals will be enrolled until 10 participants complete the first 20 weeks of 
the study with satisfactory completeness of biosample collection  
Diagnosis and Main 
Inclusion Criteria  End- stage renal disease; treatment with maintenance hemodialysis   
Study Product, Dose, 
Route  p-Inulin  8 g twice daily, administered orally  
Duration of 
administration  12 weeks  
Major Outcomes  • Intra -participant  variability in the gut microbiome composition  
• Intra -participant variability in the metabolic products of the gut microbiome  
• Tolerability of p -inulin    
Statistical Methodology  • Alpha -diversity of bacterial genera will be derived at each time point, and intra- class 
correlation coefficients,  using mixed models, will be estimated to evaluate diversity  
of multiple  observations  within each individual  
• UniFrac distances will be derived as beta diversity measures of inter -participant  
variability to characterize the compositional dissimilarity  of the microbiome between 
two individuals  
• A repeated measures MANOVA of UniFrac distances will be used to assess the 
changes of the overall microbial compositions over time.  
• Longitudinal m ixed-effect models will be applied to study change of metabolites 
before and after p -inulin treatment , and to identify the metabolites that change 
after p -inulin treatment  
• Longitudinal analyses of metabolites, with time- varying covariates (microbiome 
diversity or microbial genera) will be conducted to identify the microb ial genera 
associated with changes of metabolites due to p -inulin treatment  
HD Microbiome Study   1 
Version  V2.0, September 9, 2015  
 
CONFIDENTIAL  
Do not disclose or use except as authorized by the Hemodialysis Novel Therapies Consortium.  1 Introduction  
This document is a protocol for a human research study . This study is to be conducted according to US 
and international standards of Good Clinical Practice, applicable government regulations , and the  
research policies and procedures  in effect at the instit utions where the study  is implemented .  
1.1 Background  
A substantial body of work implicates inflammation as an important contributor to the morbidity and 
mortality associated with end -stage renal disease (ESRD)  and, in particular, to accelerated cardiovascular 
disease.1,2  However, t he etiology of unprovoked inflammation in ESR D is not well understood.  
Proposed etiologic al factors  include chronic sub- clinical infections,3 volume overload,4 oxidative stress,5 
sympathetic activation,6 malnutrition, and  vitamin D deficiency.7  Alter ations  in the intestinal 
microbiome (dysbiosis) are increasingly recognized as potential cause s of inflammation in ESRD 
patients.8-12   
The human gut harbors ~ 1014 bacteria, and the metabolic potential of the gut microbiota is enormous.13-
15  Intestinal  bacteria  perform a m ultitude of functions, and the microbial flora can be  considered a 
metabolically active endogenous “organ. ”  Under physiological conditions, the microbiota provide 
complementary functions by participating in  metabolic activities that are not  fully evolved in the human 
host such as break down of non -digest ible plant polysaccharides,16 synthesis of certain vitamins,17 
biotransformation of conjugated bile acids18 and degradation of dietary oxalates.19  Additionally, 
postnatal colonization of the intestine educates the immune system and reduces allergic responses to food and environmental antigens.
20  
Alterations in the gut microbiome have been demonstrated in  patien ts with ESRD .9,12  Individuals with 
uremia have greatly increased counts of both aerobic (~106 bacteria/ml) and anaerobic (~107 
bacteria/ml) organisms in the duodenum and  jejunum.21  The microbial flora of the lower intestinal tract  
has also been shown to be altered in patients with non -dialysis depen dent chronic kidney disease . The 
most n otable  changes are reductions  in both the Lactobacillaceae and Prevotellaceae families.9  Hida et 
al. studied the colonic composition of microbiota in healthy controls and hemodialysis patients.22   The 
number of aerobic bacteria such as  Enterobacteria and Enterococci was found to be approximately 100 
times higher in patients treated with maintenance hemodialysis than in controls.  Among anaerobic bacteria, hemodialysis patients had significantly lower organism counts for Bifidobacteria a nd higher 
organism counts for Clostridium perfringens .
22  Vaziri et al. showed significant differences in the 
abundance of 190 microbial operational taxonomic units (OTUs) between the ESRD and the normal control  individuals.  
9  In order to isolate the effect of kidney failure, the investigators examined the gut 
microbiota in nephrectomized rats.9  The study revealed substantially lower “species richness” as 
measured by the number of OTUs in the nephrectomized rats compared to the controls.  The intestinal 
dysbiosis may be a direct or indirect effect of uremia.23,24  For example, l oss of kidney function leads to 
secretion of urea into the gastrointestinal tract.   Hydrolysis of urea by bacterial urease generates  large 
quantities of ammonia which alters  the growth of commensal bacteria.23,24  Other c ontributing indirect 
factors relevant to patients with kidney failure include decreased c onsumption of dietary fiber,25-27 
HD Microbiome Study   2 
Version  V2.0, September 9, 2015  
 
CONFIDENTIAL  
Do not disclose or use except as authorized by the Hemodialysis Novel Therapies Consortium.  frequent use of antibiotics,28,29 slow colonic transit,30,31 metabolic acidosis,32,33 intestinal wall edema,34-36 
and possibly oral iron intake.37,38  
There are multiple mechanisms by which such alterations  in the gut microbiota  might contribute to 
ESRD -associated inflammation and cardiovascular disease including 1) increased production of bacteria-
derived solutes (e.g., p -cresol or p -cresyl  sulfate) that are retained in kidney failure ,39-41 and 2)  increased 
translocation into the circulation of bacterial-derived endotoxin across an impaired intestinal 
barrier.10,11,42,43  Elevated serum concentrations of total and free  p-cresol are  associated with 
cardiovascular events and mortality among patients treated with maintenance hemodialysis,44,45 and 
experimental as well as clinical studies indicate that endotoxin is involved in multiple steps of 
atherogenesis.46,47  Endotoxin provokes a host of responses by binding to  the CD14 receptor.48  Elevation 
in the concentration of soluble CD14 (sCD14), an indicator of CD14 receptor activation, is an 
independent predictor of mortality among patients treated with maintenance hemodialysis.10,11 
Prebiotics are microbial feed supplements that beneficially affect the host by improving its intestinal 
microbial balance and re -establishing symbiosis.  Treatment with the prebiotic p -inulin increases 
intestinal growth of beneficial bacteria such as bifidobacteria.49  Increases in bifidobacteria are 
associated with attenuation of inflammation and improvement in intestinal barrier function.50-52  Other 
reported effects of prebiotic supplementation include optimizing the immune response, decreasing 
endotoxin generation, and enhancing metabol ic capabilities.16,53-56 Preliminary evidence indicates that 
prebiotics are effective in reducing the plasma concentration of p-c resyl sulfate in hemodialysis 
patients.57  In a single center, non -randomized, open -label phase I/II study of hemodialysis patients, 
treatment with p -inulin for 4 weeks was accompanied by a reduction in the p -cresyl sulfate generation 
rate and a 20% decrease in its serum concentration.58  
There are important potential benefits of intervening to restore symbiosis to the gut microbiota in 
patients with ESRD.  However, before conducting clinical trials of such interventions , important gap s 
must be filled in the understanding of the composition, function and stability of the gut microbiota in 
patients with ESRD.  The purpose of the Microbiome and P -Inulin in Hemodialysis Study  is to fill some of 
these gaps in anticipation of ultimately investigating the therapeutic potential of altering the composition and/or function of the gut microbiome in this patient population.  Intensive biosample 
collection from a small number of patient s treated with  hemodialysis before, during, and after 
treatment with p -inulin will be performed in order to generate information about within -participant  and 
between -participant  variability in the composition and metabolic products  of the gut microbiome.  The 
study will also provide information about the tolerability and safety of p -inulin and the feasibility of 
biosample collection.  
1.2 Study  Agent   
p-Inulin (oligofructose -enriched inulin) is a prebioti c.  Inulin -type prebiotics are members of a larger 
group of compounds called “fructans ,” which encompasses all naturally occurring plant oligo - and poly -
saccharides in which one or more fructosyl-fructose linkages comprise the majority of glycosidic bonds.   
Inulin is present in vegetables with high fiber content such as sugar beets, leeks, onions, garlic and 
HD Microbiome Study   3 
Version  V2.0, September 9, 2015  
 
CONFIDENTIAL  
Do not disclose or use except as authorized by the Hemodialysis Novel Therapies Consortium.  asparagus.  The basic inulin, derived from chicory root , is treated with specific bacterial enzymes that 
break down the long chain inulin to the short chain oligofructose in 95% pure form.  Short -chain 
oligofructose is mixed with inulin in equal parts to prepare the final product, p -inulin.59   This 
composition allows the short chain oligofructose to be fermented in the proximal (right) colon and the 
long chain molecule, inulin, to be fermented in the distal colon.60  The end produ cts of fermentation are 
gases (such as carbon dioxide and hydrogen), lactate, and short -chain fatty acids.   
Preliminary evidence in individuals with preserved kidney function indicates that p -inulin promotes 
growth of bifidobacteria, reduces endotoxin generation, attenuates inflammation, decreases generation 
of uremic toxins and improves metabolic function.12,49,61,62   
Inulin -type prebiotics received the designation of “generally recognized as safe” in 1992.63   
1.3 Clinical Data on Prebiotics  and p- Inulin 
A large number of studies have been performed examining the effect of prebiotics in  a variety of 
conditions including obesity,64,65 HIV infection66,67 and gastrointestinal diseases.68  Bouhnik et al . showed 
that four weeks of treatment with short- chain fructo -oligosaccharides increases fecal bifidobacteria 
counts .69  In a small, randomized double -blind, placebo -controlled trial, 31 participant s who had 
received radiotherapy were randomized either to p -inulin or maltodextrin -containing placebo  for 4 
weeks.70  Lactobacillus and bifidobacterium counts decreased with radiotherapy and  recovered in the 
active treatment group  but not in the placebo group .  In another study, 49 individuals  with diabetes 
were randomized to  treatment with either  inulin 10 g/day or a maltodextrin -containing placebo  for 8 
weeks.71  In comparison with placebo, i nulin treatment improved insulin resistance and reduced plasma 
levels of lipopolysaccharide, hs -CRP and TNF -α.  
There are a limited number of studies of prebiotic  treatments in patients with ESRD  (Table 1 ).  In a pilot 
study of 22 patients  receiving maintenance hemodialysis , treatment with 2 0 g of p -inulin for 4 weeks 
reduced the generation and serum concentration of p- cresol.58  The authors reported that  
p-inuli n was well tolerated and that there was excellent adherence with treatment.  Nakabayashi 
showed that symbiotic treatment (Lactobacillus casei Shirota strain and Bifidobacterium breve Yakult 
strain as probiotics and galacto - ligosaccharides as prebiotics) t hree times per day for 2 weeks reduced 
p-cresol levels  in maintenance hemodialysis .57  
 
     
HD Microbiome Study   4 
Version  V2.0, September 9, 2015  
 
CONFIDENTIAL  
Do not disclose or use except as authorized by the Hemodialysis Novel Therapies Consortium.  Table 1 : Effect of pro -prebiotic on uremic toxins and inflammation  
Reference  Patient type (n)  Intervention  Comments  
De Preter et al.72  Healthy participants (50)  Oligofructose -enriched 
inulin  ↓ Urinary excretion of p -cresol  
Dewulf et al .64 Obese women (30)  Inulin/oligofructose  ↓Endotoxemia  
Schiffrin et al .73 Elderly participants (74)  Oligosaccharides  ↓TNF -alpha mRNA and IL -6 
mRNA  
↓Serum sCD14  
Kotzampassi et al.74  Trauma patients (65)  Probiotics  along with  
inulin, oat bran, pectin, 
and resistant starch  ↓ Rate of systemic 
inflammatory response, syndrome, infections, severe sepsis, and mortality  
Meijers et al .58 Hemodialysis  patients  (22)  Oligofructose -enriched 
inulin  ↓ Serum p -cresyl sulfate and 
generation rate  
Nakabayashi et al.57 Hemodialysis  patients (7)  Galacto -oligosaccharides 
and L. casei , and B. 
breve ↓ Serum p -cresol  
1.4 Dose Rationale and Risk/Benefits  
A dose -dependent bifidogenic effect has been observed with p -inulin.49,75  Bouhnik et al . examined the 
dose dependent effect of 8 weeks treatment with short- chain fructo -oligosaccharides (SC- FOS).62  Forty 
healthy volunteers  were randomized to one of five groups: G 0 group (SC -FOS 0 g and saccharose 20 g) 
used as placebo; G 2.5 group (SC -FOS 2.5 g and saccharose 17.5 g); G5 group (SC -FOS 5 g and sacchar ose 
15 g); G 10 group (SC -FOS 10 g and saccharose 10 g); and G 20 group (SC -FOS 20 g and saccharose 0 g).  
Bifidobacteria counts at Day 8 were greater in groups G 10 and G 20 compared with G 0 and G 2.5.  Total 
anaerobes increased at the 10  g daily dose, but not  at lower doses, while no significant differences were 
found for Bacteroides, Lactobacillus, or Enterobacteriaceae.76  Excess flatus was significantly more 
frequent in participants consuming G 20.  Th e authors concluded that for healthy individuals consuming 
their usual diets, 10 g/day is the optimal dose in terms of tolerability and efficacy with respect to 
increasing fecal bifidobacteria.  Gibson et al . reported that FOS at 15 g/day in three divided doses 
increased the proportion of Bifidobacteria from 6% to 22% in healthy adults during two weeks of use.  
The effect on Bifidobacteria was accompanied by significant decreases in Bacteroides, Clostridia, and 
Fusobacteria.49  Meijers et al. showed that a dose of 20 g/day is tolerated by patients with ESRD;  
however, report s of abdominal symptoms  were frequent .77   Thus, the doses of 10 g and 20 g daily 
resulted in significant increases in fecal B ifidobacteria compared to lower doses, but with more 
abdominal symptoms at the higher dose .49,59,76,78 
In the current study, all participants will receive p- inulin at a dose of 8 g two times per day for a total 
daily dose of 16 g.  Based on experience in non -ESRD popu lations,  it is anticipated  that this dose will 
have accept able  tolerability  and sufficient  efficacy .49, 62   
HD Microbiome Study   5 
Version  V2.0, September 9, 2015  
 
CONFIDENTIAL  
Do not disclose or use except as authorized by the Hemodialysis Novel Therapies Consortium.  1.4.1 Risks  
The most common side effects o f p-inulin include gastrointestinal symptoms such as flatulence, bloating, 
abdominal distension, loose stools, and increased stool frequency.42  These symptoms have been more 
frequently reported with inulin doses in the range of 15 to 30 g per day than with lower doses.79,80 
Gastrointestinal symptoms will be ascertained in this study using the Gastrointestinal Symptom Rating 
Scale .81  Detailed collection of g astroin testinal symptoms  is important for  this population because these  
symptoms, particularly constipation, occur frequently in ESRD  patients  in the absence of p -inulin 
treatment.  P articipants are not expected to benefit from participating in th is study .  The d ata obtained 
from this study will be used to inform  the design of a larger, placebo -controlled  study to assess the 
therapeutic potential of altering the gut microbiome with p -inulin in hemodialysis patients.   
2 Study Objectives  
The overarching hypothesis motivating this exploratory study of variability of the human gut 
microbiome is that treatment with oligofructose enriched inulin (p- inulin) will alter the composition 
and/or function of the gut microbiome, and thereby reduce the  generation of gut -derived uremic toxins, 
improve gut barrier function and attenuate systemic inflammation in patients treated with maintenance 
hemodialysis .  In order to design a future clinical trial to te st this hypothesis, information is needed 
about t he following parameters from individuals  receiving maintenance  hemodialysis:  
1) Intra -participant  and inter -participant  variability in the metabolic products and composition of 
the gut microbiome  
2) Impact of p -inulin on the metabolic products  and composition of the gut microbiome  
3) Tolerability of p- inulin  
4) Safety of p -inulin  
5) Feasibility of collecting stool samples in this patient population  
2.1 Primary  Objectives  
• To evaluate the within -participant  variability of gut bacteria- derived metabolites and gut 
bacterial composition over an 8 -week period during which there is no protocol -driven treatment  
• To evaluate, using each participant  as  his/her own control, whether treatment with p -inulin for 
12 week s alters gut bacteria- derived metabolites and gut bacterial composition  
2.2 Secondary  Objectives  
• To evaluate, using each participant  as his/her own control, whether p -inulin alters levels of 
selected circulating inflammatory markers and mediators  
• To assess between -participant  variability of gut bacteria- derived metabolites and gut bacterial 
composition over an 8 -week period during which there is no protocol -driven treatment  
• To assess between -participant  variability of gut bacteria- derived metabolites and gut bacterial 
composition during a 12-week period of treatment with p -inulin  
• To evaluate the tolerability of p- inulin administered at a total daily dose of 16 g 
• To evaluat e the short -term safety of p -inulin administered at a total daily dose of 16 g  
• To assess adherence to p -inulin treatment  
HD Microbiome Study   6 
Version  V2.0, September 9, 2015  
 
CONFIDENTIAL  
Do not disclose or use except as authorized by the Hemodialysis Novel Therapies Consortium.  • To explore the willingness of hemodialysis patient s to enroll in a study requiring repeated 
collection of stool samples  
• To explore participant adherence to the stool sample collection requirements  
• To identify barriers to adhering to stool sample collection 
3 Study Design  
3.1 General Design  
This is a non -randomized, open -label, crossover study .  Participants will be followed during 3 sequential 
phases: 1) no intervention  (8 week observational period) , 2) p -inulin administration  (12 week treatment 
period) , and 3) no intervention ( 8 week observational period) .  The visit and s tool and blood collection 
schedule for each phase  is depicted in Figure 1 and a detailed table of study procedures is provided in  
Section 15.1 .  Study participants will be recruited from four sites in the U.S.   
Figure 1.  Visit and Biosample Collection Schedule  
 
3.2 Study Endpoints  
3.2.1 Primary  Endpoints  
Microbiome Characterization  primary endpoints include : 
1. Within -participant  variability in the metabolomic  profile and targeted metabolites / 
inflammatory markers during the no treatment phases  
2. Within -participant  variability in the metabolomic profile and targeted metabolites / 
inflammatory markers during the p- inulin treatment phase  
3.2.2 Secondary  Endpoints  
Microb iome Characterization  secondary endpoints include : 
1. Within -participant  change in the metabolomic profile and targeted metabolites / inflammatory 
markers after p -inulin treatment compared with pre -treatment  

HD Microbiome Study   7 
Version  V2.0, September 9, 2015  
 
CONFIDENTIAL  
Do not disclose or use except as authorized by the Hemodialysis Novel Therapies Consortium.  2. Within -participant  variability in the bacterial com position of the stool during the no treatment 
phase  
3. Within -participant  variability in the bacterial composition of the stool during the p -inulin 
treatment phase  
4. Within -participant  change in the bacterial composition of the stool after p -inulin treatment 
compared with pre -treatment  
5. Differences in the above measures between diabetic and non -diabetic participants  
6. Within -study cohort variability in the metabolomic profile and targeted metabolites / 
inflammatory markers during the no treatment phase  
7. Within -study  cohort variability in the metabolomic profile and targeted metabolites / 
inflammatory markers during the p- inulin treatment phase  
8. Within -study cohort change in the metabolomic  profile and targeted metabolites / inflammatory 
markers after  p -inulin treatment compared with pre -treatment 
 
Tolerability  and S afety  endpoints include : 
1. Gastrointestinal symptoms  
2. Early discontinuation of p -inulin  
3. Reduction in p -inulin dose  
4. Adverse events  
 
Study Feasibility  endpoints include:  
1. Enrollment refusal rate   
2. Proportion of completed protocol -specified stool sample collections  
3. Proportion of completed blood sample collections  
4. Adherence to p- inulin assessed by packet  counts  
5. Participant withdrawal during each  phase of the study  
4 Participant  Selection and Withdrawal  
4.1 Inclusion Criteria  
a) Maintenance hemodialysis therapy for end -stage renal disease  
b) Age ≥ 18 years  
c) ≥90 days since hemo dialysis initiation  
d) Self-reported a verage stool frequency of at least 1 every  other day  
e) For women of childbearing potential, willingness to use a highly effective method of birth 
control for up to 4 weeks after the last dose of p-inulin .  See Section 4.2.1  for definition of 
childbearing potential and acceptable methods of birth control.  
f) Ability to provide informed consent  
4.2 Exclusion Criteria 
a) Use of pre biotics  or pro biotics during the past 8 weeks    
HD Microbiome Study   8 
Version  V2.0, September 9, 2015  
 
CONFIDENTIAL  
Do not disclose or use except as authorized by the Hemodialysis Novel Therapies Consortium.  b) Consumption of probiotic  yogurt during the past 2 weeks  
c) Use of antibiotics within the past 8 weeks  
d) Presence of HIV infection , chronic wound infection, osteomyelitis,  or current  hemodialysis 
vascular access infection  
e) Inflammatory bowel disease, chronic diarrhea, current C. difficile infection  
f) Cirrhosis or chronic active hepatitis   
g) Anticipated kidney transplant ation , change to peritoneal dialysis, or transfer to another dialysis 
unit within 9 months   
h) Expected survival less than  9 months  
i) Pregnancy, anticipated pregnancy, or breastfeeding  
j) Incarceration  
k) Participation in another intervention study  
l) Severe anemia defined as hemoglobin < 9.0 g/dl within the past 4 weeks as documented in the 
dialysis unit patient record  
4.2.1 Women of Childbearing Potential  
Women of childbearing potential include any female who has experienced menarche and who has not 
undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral 
oophorec tomy) or is not postmenopausal.  Postmenopaus al is defined as:  
• Amenorrhea for ≥ 12 consecutive months without another cause or  
• Women with irregular menstrual periods and a documented serum follicle stimulating hormone 
(FSH) level > 35 mIU/mL or  
• Women on hormone replacement therapy (HRT)  
Women who are using oral contraceptives, other hormonal contraceptives (vaginal products, skin patches, or implanted  or injectable products), or mechanical products such as an intrauterine device or 
barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy , or who  are practicing 
abstinence , or have a  partner who is sterile (e .g., vasect omy) should be considered to be of childbearing 
potential.  
Acceptable methods of highly effective birth control include:  
• Condom with spermicide  
• Diaphragm and spermicide  
• Cervical cap and spermicide  
• Hormonal contraception  
4.3 Recruitment  
Participants will be recruited from four  Clinical Centers  with a general goal of enrolling 3-5 participants 
at each site.  Participants at dialysis units affiliated with investigator and co -investigator practices will be 
screened for eligibility.   In addition to active screening of dialysis unit patient rosters by study 
personnel, informational handouts and brochures may be disseminated at affiliated dialysis units  to 
allow potential participants to learn about the study and to contact investigators if interested.  All study 
HD Microbiome Study   9 
Version  V2.0, September 9, 2015  
 
CONFIDENTIAL  
Do not disclose or use except as authorized by the Hemodialysis Novel Therapies Consortium.  materials must be approved by local Institutional Review Boards ( IRB) before dissemination to potential 
study participants.   
Dialysis unit laboratory studie s, medical records at the investigator’s institution, and treatment or 
medical history records at the dialysis  unit will be reviewed to assess eligibility for enrollment.  No study -
specific testing is required to confirm eligibility, other than a  serum pregnancy test for women of 
childbearing potential.  Before  approaching potential participants , the treating nephr ologis t will be 
contacted to assess suitability for enrollment.  
Once preliminary eligibility is confirmed, written informed consent will be obtained by a qualified 
investigator or study site designee during an in -person visit.  This visit ma y take place either at the local 
dialysis unit or at the investigator’s institution  in accordance with investigator and participant 
preferences.   
Recruitment will continue until a total of 10 participants have satisfactorily completed  the first 20  weeks 
of the study protocol.   
Participants will be compensated for providing stool samples.  Each Clinical Center is responsible for 
developing a compensation plan and schedule, and distributing payment.   
4.4 Early Withdrawal of Participants  and Early Study Termina tion  
4.4.1 Early Withdrawal of Participants  
Reasons for premature withdrawal include  pregnancy, death, and withdraw al of consent.  Participants 
who are not able or willing to continue taking the study agent will be encouraged to remain in the study 
and continue biosample collection.   
4.4.2 Dose Reduction and Discontinuation of p-I nulin  
Participants who are unable to tolerate  p-inulin at  a total dose of 1 6 g per day ( 8 g twice daily) will have 
the dose reduced to a total dose of 8 g per day ( 4 g twice daily) .  If the participant is unable to tolerate  a 
total daily dose of 8 g, p-inulin will be discontinued.   
If p-inulin  is discontinued , study visits , sample collection and other procedures will cont inue as planned 
unless the participant withdraws consent for follow -up.   
Participants who have reduction in dose or discontinuation of p- inulin because of intolerance are 
permitted, at the discretion of the site investigator, to resume taking p- inulin within the 12-week dosing 
phase.  
5 Study Procedures  
5.1 Study Visit Schedule  
A schedule of study visits and procedures is provided in the Study Procedures Table in Section 15.1 . 
HD Microbiome Study   10 
Version  V2.0, September 9, 2015  
 
CONFIDENTIAL  
Do not disclose or use except as authorized by the Hemodialysis Novel Therapies Consortium.  5.1.1 Pre- screening Activities  
Patients  at dialysis units affiliated with investigator and co -investigator practices will be screened for 
eligibility.  Clinical Center s tudy personnel will review dialysis unit records and other medical records  to 
assess eligibility.  The treating nephrologist for a potentially eligible patient will be contacted to further 
assess eligibility and obtain permission to contact the patient.     
5.1.2 Screening/Baseline Visit  
Patients  who appear  eligible based on pre -screening will be approached in person to determine inter est 
in participation  and confirm eligibility.  S tudy personnel will discuss the study goals and procedures with 
the potential participant in detail.  If the patient agrees  to participat e in the study, study personnel will 
review and assess understanding of  the entire informed consent form before  obtaining written informed 
consent from the participant.  The consenting process will be performed by a qualified investigator or 
study site designee.  Informed consent will be obtained and documented before any study procedures are performed.  
The screening and baseline activities  may take place over a single or multiple  visits.   
Screening/Baseline Visit Activities  
• Informed consent process  
• Collection of baseline data including demographic s, medical history, and medication use 
including recent and current use of prescription  products , over -the-counter products, herbal 
supplements,  vitamins, and prebiotic  and probiotic use in any form.  In addition, medical records 
from the dialysis facility  will be reviewed  to capture any non -reported data on recent 
medication use.  
• Determination of eligibility  
• Blood draw  for baseline measurements ( 13 mL); blood draw must be performed before the  start 
of the dialysis session  
• Blood draw  for serum pregnancy t est for women of childbearing potential   
• Instruction in stool sample collection  and storage  
• Dietary assessment using food frequency questionnaire  
• Gastrointestinal symptom assessment questionnaire  
Enrolled participants will be instructed not to change their dietary pattern s, if possible, during the study.   
See Section 5.2  for details regarding the blood and stool sample  collection schedule.   
5.1.3 Week  4, 8, 12, 16, 20, 24, and 28 Visits  and Weekly Telephone Contacts  
Participants will have in -person study visits at W eeks 4, 8, 12, 16, 20, 24  and 2 8.  At each study visit, 
participants will be asked about emergency room visits, hospital admissions or any significant clinical 
events that occurred since the last visit.  On a weekly basis, participants will be queried on antibiotic use 
in the previous week, and dialysis records will be reviewed for antibiotics administered at the dialysis unit.  During the dosing phase, participants will also be asked questions to assess adherence with  
p-inulin.  
HD Microbiome Study   11 
Version  V2.0, September 9, 2015  
 
CONFIDENTIAL  
Do not disclose or use except as authorized by the Hemodialysis Novel Therapies Consortium.  Dietary assessment using the Block F ood Frequency Questionnaire (https://nutritionquest.com ) will be 
administered at Baseline and W eeks 8 (end of pre-treatment phase), 20 (end of treatment phase), and 
28 (end of post-treatment phase). 
Week 4 Visit  
• Information on clinical events and current use of medications will be collected.   
• Gastrointestinal symptom assessment questionnaire will be administered.  
Week 8 Visit  
• Information on clinical events and current use of medications will be collected.   
• Gastrointestinal symptom assessment questionnaire will be administered.  
• Dietary assessment using a food frequency questionnaire will be administered to assess dietary 
patterns  before  starting p -inulin.   
• A four week supply of p-inulin  will be dispensed to the participant along with instructions  for its 
use. 
• To assess adherence to the study protocol, participants will be instructed to ke ep all unused 
study agent packets  and bring them to the Week 12 visit.   
Week 12 Visit  
• Information on clinical events and current medication  use will be collected.   
• Gastrointestinal symptom assessment questionnaire will be administered.  
• Tolerability of p-inulin will be assessed  by participant self- report .  If participant has not been 
able to t olerate 1 6 g total daily dose, the dose may be reduced to a total daily dose of 8 g.   
• Study personnel will collect, count and record the number of unused p- inulin packets.  
• A four week supply of p -inulin  will be dispensed.  
• To assess adherence to the p-inulin treatment schedule , participants will be instructed to ke ep 
all unused study agent packets and bring them to the Week 16  visit.   
Week 16 Visit  
• Information on clinical events and current medication  use will be collected.   
• Gastrointestinal sympto m assessment questionnaire will be administered.  
• Tolerability of p-inulin will be assessed by participant self- report.  If participant has not been 
able to tolerate 16 g total daily dose, the dose may be reduced to a total daily dose of 8 g.   
• Study personnel will collect, count and record the number of unused p- inulin packets.  
• A four week supply of p -inulin  will be dispensed.  
• To assess adherence to the p -inulin treatment schedule , participants will be instructed to ke ep 
all unused study agent packets and b ring them to the Week 20  visit.  
Week 20  Visit   
• Information on clinical events and current medication  use will be collected.   
• Gastrointestinal symptom assessment questionnaire will be administered.  
HD Microbiome Study   12 
Version  V2.0, September 9, 2015  
 
CONFIDENTIAL  
Do not disclose or use except as authorized by the Hemodialysis Novel Therapies Consortium.  • Dietary assessment using a food frequency questionnaire will be administered  to assess dietary 
patterns during the p -inulin treatment period.   
• Tolerability of p-inulin will be assessed .  Study personnel will collect, count and record the 
number of unused p-inulin packets.      
Week 24 Visit  
• Information on clinical events and current medication  use will be collected.  
• Gastrointestinal symptom assessment questionnaire will be administered.  
Week 2 8 Visit (Study Completion)  
• Information on clinical events and current medication  use will be collected.     
• Gastrointestinal symptom assessment questionnaire will be administered.  
• Dietary assessment using a food frequency questionnaire will be administered  to assess dietary 
patterns during the p -inulin treatment peri od.   
5.2 Biosample Collection Procedures and Schedule  
Stool samples will be collected at baseline , once weekly during weeks 1–7, 10–18 and 21-28, and twice  
weekly during weeks 8, 9, 19, and 20.   The sample collection during weeks 21-28 (after p -inulin 
treatme nt) will allow detection of delayed alterations in response to p -inulin and will provide 
information about the durability of p -inulin effects . 
Stool specimen s will be obtained  by study participants.  Participants will be provided a commercial 
“toilet hat” stool specimen collection kit (specimen container, shipping box, S tyrofoam cooler, and cold 
packs; Fisherbrand Commode Specimen Collection System; Thermo Fisher Scientific, Waltham, MA, 
USA) , sample aliquot tubes, and gloves  at the  Baseline  visit and as needed for resampling.  Participants 
will be instructed on how to aliquot and store samples  before bringing them to the research team .   
Participants will bring the aliquoted stool samples on ice packs in the  closed Styrofoam cooler to the 
clinical center or dialysis unit.  Research staff will process samples according to C ore Laboratory  
specifications and store at -80 °C for future shipment to the Core Laboratory.   The aliquoting of samples 
is performed before  freezing in order to mi nimize the number of freeze -thaw cycles.   Detailed 
information regarding  stool sample collection, storage, shipping, and participant training is provided in 
the Manual of Procedures (MOP).   
Participants who do not provide the required number of stool samp les will continue to be followed for 
the full duration of the study and will continue to be encouraged to provide samples in accordance with 
the protocol schedule.  
All b lood samples will be obtained on dialysis days before  the start of the dialysis session  and before any 
interaction between the blood and the dialyzer membrane .  The volume of each  sample will be 13 mL.  
Study staff will review the most recent hemoglobin lab results in the dialysis unit medical record.  If this result is less than 9.0 g/dl, b lood will not be collected until  the hemoglobin value is 9.0 g/dl  or greater.  
HD Microbiome Study   13 
Version  V2.0, September 9, 2015  
 
CONFIDENTIAL  
Do not disclose or use except as authorized by the Hemodialysis Novel Therapies Consortium.  Blood specimens will be processed and aliquoted according to the Core Laboratory specifications.  
Samples will be stored at - 80° C for future shipment to the Core Laboratory .  The MOP provides detailed 
information on blood specimen processing.  
5.2.1 Weeks 1-7 
Stool and blood samples will be collected one time each week.  Participants will be provided with 
written  instructions about  how to collect and store stool samples.   
5.2.2 Weeks 8 -9 
During the week before  and the week after the change from no -treatment to p -inulin treatment, the 
frequency of stool sample collection will increase to two times per week.  Blood collection will occur one 
time each week.     
5.2.3 Weeks 10-18 
Stool and blood samples will be collected one time each week.   
5.2.4 Weeks 19-20 
During the week before  and the week after the  change from p -inulin treatment to post -treatment,  the 
frequency of stool sample collection will increase to two times per week.   Bloo d collection will occur 
one time each week.      
5.2.5 Weeks 21-28 
Stool and blood samples will be collected one time each week.   
5.3 Stool and Blood Analyses  
5.3.1 Metabolites and Inflammatory Markers.  
Metabolites and inflammatory markers of interest that provide functio nal information about the gut 
microbiota or the host response are shown in Table 2 .  Both non -biased and targeted metabolomic  
profiling of the stool  and blood will be performed. Inflammatory markers will be measured in the plasma 
samples.  
 
Filtered fecal water or plasma samples  will be used  for the mass spectrometry -based  metabolomic 
profiling. The process of metabolite extraction will include internal standards and follow standard protocols.  The resulting extract will be divided into a liquid chromatography fraction and a gas 
chromatography fraction.  
   
 
  
 
HD Microbiome Study   14 
Version  V2.0, September 9, 2015  
 
CONFIDENTIAL  
Do not disclose or use except as authorized by the Hemodialysis Novel Therapies Consortium.  Table 2.  Stool and Blood Analytes of Interest  
 Stool  Blood  
Short chain fatty acids (butyrate, propionate, acetate)  + + 
Trimethylamine N oxide  + + 
Phenols  
p-Cresyl sulfate  
p-Cres yl glucuronide  
Phenyl sulfate  
Phenyl glucuronide  
α-N-phenylacetyl -L-glutamine  
Phenylpropionylglycine  
Hippuric acid  
4-hydroxybenzoate  
Phenylacetylglycine   
+ 
+ 
+ 
+ + + 
+ 
+ 
+  
+ + 
+ 
+ + + 
+ 
+ 
+ 
Indoles  
Indoxyl sulfate  
Indoxyl glucuronide  
5-hydroxyindole  
Indole -3-prioonic acid  
Indole -3-acetic acid   
+ + + 
+ 
+  
+ 
 
 
 
+ 
Polyamines  + + 
Metabolites of urea metabolism  + + 
Metabolites of creatinine metabolism  + + 
Allantoin  +  
Cytokines  
IL-1β 
IL-2 
IL-4 
IL-6 
IL-10 
IL-17 
IL-22 
TNFα    
+ 
+ + + 
+ 
+ + 
+ 
Endotoxin   + 
Myeloperoxdase  (MPO)   + 
hsCRP   + 
HMGB1   + 
TNF-R1  + 
TNF-R2  + 
Lipopolysaccharide binding protein (LBP)   + 
sCD14   + 
 
Liquid chromatography/Mass spectrometry (LC/MS):  A 6590 Triple Quadrupole  mass spectrometer 
(QQQ, Agilent Technologies, Santa Clara, CA) connected in the front end to Ultra Performance Liquid 
Chromatography will be used for Multiple Reaction Monitoring -based target metabolic quantification. 1 
Data acquisition in QQQ will be controlled using the Mass Hunter data acquisition software. Findings will be confirmed using selected reaction monitoring (SRM).  
 
HD Microbiome Study   15 
Version  V2.0, September 9, 2015  
 
CONFIDENTIAL  
Do not disclose or use except as authorized by the Hemodialysis Novel Therapies Consortium.  Gas chromatography/Mass spectroscopy (GC/MS):   The derivatized sample s will be injected into GC -MS, 
which is run using electron impact as the ionization source.  Similar to the LC -based platform, detection 
of the metabolite would involve detection of its precursor followed by additional accurate mass 
detection of the produc t ions for the precursor by SRM.  Each of the controls (standard mixture and liver 
pool) will be included multiple times in the randomization scheme such that sample preparation and 
analytical variability are constantly monitored. Furthermore, analysis of each clinical sample will be 
followed by at least two blank runs to prevent any carryover of metabolites between samples.  
The bacterial genomic DNA from feces will be extracted using MO BIO PowerSoil DNA Isolation Kit (MO 
BIO Laboratories). DNA extraction and 16S rRNA gene sequencing will be performed with methods 
consistent with those developed for the NIH -Human Microbiome Project. Briefly, the microbiome will be 
measured by deep sequencing of 16S rRNA genes on the Illumina MiSeq platform. 16S rRNA genes 
contained in every sample will be isolated by amplifying multiple regions of the 16S rRNA genes with 
barcoded, degenerate primers that target the V4 hy pervariable domain of the gene.  These primers also 
contain adapters for MiSeq sequencing so that the PCR products may be pooled and sequenced directly. 
Pooling will enable us to achieve a depth of sequencing of at least 5,000 reads per sample.  Rarefaction 
and collector’s curves of microbial community d ata will be constructed using sequence data for each 
sample to ensure that we are sampling the majority of the diversity present.  
 A purposeful approach to analyzing the stored blood and stool samples will be used.  Initial 
measurements will be made on stool and blood samples obtained from  a subset of the time points . 
Selection of  additional time points for sample  analysis will be made based  on the  initial findings.  For 
example, if measurements made on samples obtained at weeks 1 , 4 and 8 indicate that there is limited 
within -participant  variability over an 8 -week period,  performing additional measurements using  samples 
from weeks 2, 3, 5, 6, and 7 will have low priority.  However, if within- participant  variability is evident 
using the samples from weeks  1, 4 and 8, performing measurements on the weekly samples , and/or the 
within -week samples  will be of greater interest .   
6 Study Agent   
6.1 Description  
p-Inulin (oligofructose -enriched inulin) is a prebiotic. p-Inulin will be provided in individual packets that  
each contain 2 g of product . This study will utilize Prebiotin Prebiotic Fiber Stick Pac 2  g distributed by 
Jackson GI Medical.  
6.2 Treatment Regimen   
All participants will take a  p-inulin dose of 8 g two times per day for a total daily dose of 16  g.  For each 
dose, the contents of four  packets will be added by the participant to 100 -200 ml of any type of liquid  
and taken orally .  Treatment duration is 12 weeks.  If a dose reduction of the study agen t is required 
during the treatment phase, the investigator  will instruct the participant to use only 2 packet s (4 g) twice 
daily  for a total daily dose of 8 g per day.  The study agent will be discontinued if further dose reduction 
is required.  
HD Microbiome Study   16 
Version  V2.0, September 9, 2015  
 
CONFIDENTIAL  
Do not disclose or use except as authorized by the Hemodialysis Novel Therapies Consortium.  6.3 Administration of Study Agent  
Study agent  will be prepared by the University of Pennsylvania Investigational Drug Service (IDS) , the 
Central Pharmacy for this study.  Each study agent  kit will contain a 4 -week supply.  The participant will 
receive a 4 -week supply of study agent at the Week 8 , 12,  and 16  visits.   
6.4 Receiving, Stor ing, Dispensing and Retur ning Study Agent  
6.4.1 Recei ving Study  Product (p -Inulin)  Supplies  
The Central Pharmacy will distribute study agent kits to the research pharmacy at each Clinical Center.  
Each Clinical Center research pharmacy will be responsible for maintaining detailed records regarding 
the receipt of study agent .  General study product accountability , participant -specific study product 
Accountability, and if necessary, Shipment Tracking Accountability Logs will be main tained by the site 
pharmacist to document study agent  use.  Documentation includes study product receipt, storage, 
dispensing, and final disposition.   
6.4.2 Storage  
The boxes containing p -inulin will be stored in a locked cabinet at the University of Pennsylvan ia 
Investigational Drug Service  until shipment to the  Clinical Center research pharmacy .  After receipt by 
the Clinical Center, the study agent will be stored at the research pharmacy  until distribution to the 
participant.  
The study agent  will be stored at 25°C (77°F) with excursions of 15-30°C (59 -86°F)  permitted.  
6.4.3 Dispensing  Study Agent  
Upon enrollment of a participant, study personnel will request from the Central Pharmacy that three 
study agent kits are sent to the Clinical Center research pharmacy.  The s tudy agent  will be dispensed by 
the Clinical Center research pharmacy in 4 -week supplies at the Week 8, 12, and 16  visits to either an 
appropriate member of the research team or to the participant in accordance with Clinical Center polic ies and preferences.  
6.4.4 Return or Destruction of Study Agent  
Participants will return any unused study agent at the Week  12, 16, and 20  visits.   
Returned product will be counted and recorded by study staff and documented on the Study Agent Dispensing and  Accountability log.   
At the completion of the study, there will be a final reconciliation of study agent shipped, study agent 
consumed, and study agent  remaining.  This reconciliation will be logged on the study agent 
reconciliation form, signed and dated.  Any discrepancies noted will be investigated, resolved, and documented before  the return or destruction of unused study agent .  Study agent  destroyed on site will 
be documented in the study files.  
HD Microbiome Study   17 
Version  V2.0, September 9, 2015  
 
CONFIDENTIAL  
Do not disclose or use except as authorized by the Hemodialysis Novel Therapies Consortium.  6.5 Participant  Adherenc e Monitoring  
Adherence to the study agent will be assessed by counts of returned packets at the Week 12, 16, and 20  
visits  and from participant self-report . 
6.6 Concomitant Therapy  
Medication use (both oral and intravenous) will be collected at baseline  and thro ughout the course of 
the study.  Information about over the counter medications, vitamins, herbal supplements, and 
prebiotic and  probiotic supplements in any form will also be collected.  Appropriate sources for 
obtaining this information include the participan t, the medical record , and treating clinicians .   
Participants will be told not to eat probiotic yogurt throughout study participation.  Participants will 
continue their medications including anti -hypertensive agents, phosphate binders, vitamin D 
preparations, erythropoietin stimulating agents, and oral or intravenous iron as prescribed by the treating physician.  
Patients  with chronic antibiotic use for any specified indication will not be enrolled.  
7 Statistical Plan  
7.1 Sample  Size Determination  
The target sample size is 10 participants who complete phase 1 and phase 2 and provide sufficient 
number of stool samples.  “Sufficient” number of stool samples  is defined as 2 samples during Weeks 1 -
4, 2 samples during W eeks 5 -8, 3 samples during Weeks 9 -14, and 3  samples during Weeks 15 -20.   
Additional participants will be enrolled (up to 10 additional participants) as needed to obtain a total of 10 participants who meet the follow -up duration and sample sufficiency criteria.  Participants who do 
not meet the sam ple sufficiency criteria will continue in the study and will continue to be encouraged to 
provide samples in accordance with  the protocol schedule.  Because of the high prevalence of diabetes 
mellitus among patients with ESRD and potential differences in t he gut microbiome between patients 
with and without diabetes, the study will aim to have approximately 50% of participants with diabetes 
and 50% of participants without diabetes. Participants will be enrolled from 4 centers.  
This repeated measures study de sign will provide important preliminary data on week -to-week 
variability of gut microbiome and on the effects of p -inulin on microbiome composition.  Referring to 
relevant simulations ,
82 the power for detecting various changes in microbiome composition based on 10 
participants , before and after p -inulin treatment, can be estimated.  Figure 2  shows the power for 
detecting changes in community membership, even ness, richness and line ages for various effect sizes 
based on distance -based MANOVA analysis using different distances based on a 2D circle simulation.  
Figure 3 shows the power of change of taxa clusters of various abundances based on simulating data on 
a phylogenetic tree.  Fo r a sample size of 10, we have adequate power to detect moderate to large 
effect sizes.  
Based on a paired t -test, a sample size of 10 can detect an effect size smaller than 1.7 of p -inulin on 
metabolite change s assuming that 25 metabolites will be tested and that adjustment for multiple 
HD Microbiome Study   18 
Version  V2.0, September 9, 2015  
 
CONFIDENTIAL  
Do not disclose or use except as authorized by the Hemodialysis Novel Therapies Consortium.  comparisons will be conducted within the framework outlined by Benjamini and Hochberg  for 
controlling the false discovery rate (FDR).83  The multicenter nature of the study will provide information 
about the feasibility of stool sample collection for future multicenter studies of the gut microbiome.   
 
 
Figure 2. Power to Detect Composition Changes  
 

HD Microbiome Study   19 
Version  V2.0, September 9, 2015  
 
CONFIDENTIAL  
Do not disclose or use except as authorized by the Hemodialysis Novel Therapies Consortium.   
Figure 3.  Power to Detect Changes of Taxa Clusters  
7.2 Missing  Data  
In general, missing data will not be imputed.  Every effort will be made to use statistical methods that 
are robust to missingness, and the number of participants  included with each analysis will be given with 
the results.  
7.3 Statistical Methods  
7.3.1 Sequence Data Processing  
Longitudinal stool samples will be analyzed by sequencing of 16S rRNA gene tags to characterize bacterial populations.   Sequence data will be processed using QIIME, augmented by the R package 
QIIMER (http://cran.r -project.org/web/packages/qiimer).   Taxonomy will be assigned to the sequences 
using Ribosomal Database Project (RDP) for 16S, augmented by analysis of specific sequences using BLAST. The 16S t ag sequences will be collected into operational taxonomic units (OTUs) with 97% 
sequence identity and samples summarized as vectors of proportions.   

HD Microbiome Study   20 
Version  V2.0, September 9, 2015  
 
CONFIDENTIAL  
Do not disclose or use except as authorized by the Hemodialysis Novel Therapies Consortium.  7.3.2 Analysis of Microbial Composition  
Stool samples will be compared longitudinally within individual subjects,  and between groups.  
Variability of gut microbiomes across the first 8 weeks, and during the p -inulin treatment period will be 
assessed at both the microbial diversity level, and the individual taxon level.   The analysis will be 
performed at the overall microbiome composition level by calculating the alpha and beta diversities 
using UniFrac distances.   Principal coordinate analysis (PCA) based on the UniFrac distances will be 
performed and used to display the samples in PCA space.  
For each individual, the alpha- diversity of bacterial genera will be calculated at each time point.  Alpha-
diversity is used to describe the structure of the bacterial community based on the number of species, and the proportion in which each species is represented in the commun ity.  The alpha diversity as a 
measurement will be analyzed using the repeated measurement ANOVA .  To measure inter -individual 
variability, the beta diversity will be calculated to measure the compositional dissimilarity between two individuals at a given time point.  To account for the phylogenetic tree information of the bacterial taxa, UniFrac distances (both weighted and unweighted) will be used as the beta diversity measure.  Within -
individual distances and between -individual distances will be compared  and clustering analysis of all the 
samples will be performed using the UniFrac distances.   A repeated measure distance-based MANOVA 
will be used to assess the changes of the overall microbial compositions over time.  The i ntraclass 
correlation coefficient will be determined using mixed models, with the individual as the cluster and 
multiple diversity observations as groups.   The beta diversity will be applied with PREMANOVA and 
kernel -based regression in order to test the overall microbiome compositional differences between 
groups and over times.   The genus -level analysis will be analyzed using rank -based tests using false 
discovery rate (FDR) control procedure s for multiple comparisons to identify the bacterial genera that 
change their abundances over time and show different profiles between treatment/control 
periods.   Linear mixed -effect models will also be explored after appropriate transformation of the 
proportional data (e.g., logistic transformation).  In addition to  evaluating the intra- individual  and inter -
individual  variability at the overall microbial compositional level, such variability will be evaluated at the 
taxon level, e.g., at each genus level.   From 16S data, estimates will be obtained of the relative 
proportion of each of the bacterial genera observed in the data.  For each bacterial taxon, a zero 
enriched beta regression model will be fit with random effects to assess the intra -individual  and inter -
individual  variability, both in terms  of presence/absence and  also the relative abundances.  
The effects of p -inulin on gut microbiome compositions  will be assessed  using repeated measurements 
ANOVA with alpha -diversity as the outcome.   This assesses whether p -inulin has any effect on the 
overall gut microbial diversity.  The  distance -based MANOVA  will be applied  to test the effect of p -inulin 
on overall microbial compositions, where UniFrac distances will be used.  To identify the bacterial taxa 
that show differential abundances before and after p -inulin treatment, a zero -enriched beta regression 
model will be fit with random effects to take into account week -to-week variability.  Similar analyses will 
be performed to compare the microbiome compositions between week 1 and study comp letion and 
between treatment stop and the end of study.   
HD Microbiome Study   21 
Version  V2.0, September 9, 2015  
 
CONFIDENTIAL  
Do not disclose or use except as authorized by the Hemodialysis Novel Therapies Consortium.  We will also explore various functional data analysis methods to identify the bacterial taxa with 
differential abundances after the p- inulin treatment, where the taxonomic profil e of each individual 
measured over 8 weeks of time is treated as functional data.  The paired functional data can be modeled 
with  mixed effects model s using basis functions or penalized splines84.  We can then test the overall 
mean function differences before and after p- inulin  treatment using a likelihood ratio test.  We will 
consider different transformation of the proportional data before fitting the mixed effects model.  
Microbiome d ifferences between diabetic  and non- diabetic participants  before  p-inulin treatment  will 
be explored taking into account week -to-week variability using a mixed -effects model for alpha 
diversity, and a zero -enriched regression analysis for each of the taxa.  
7.3.3 Analysis of metabolomic profile and targeted metabolites  
For each of the metabolites, standard mixed -effects models will be applied to assess the intra - and inter -
individual variability.  Nonlinear random effects models will be fit t o account for possible heterogeneity 
in the intra -individual variance structure.  Standard repeated measureme nt ANOVA and mixed -effect 
models will be applied to study change of metabolites before and after p -inulin treatment and to 
identify the metabolites that change after p -inulin treatment.  Adjustment for multiple comparisons will 
be conducted within the framework outlined by Benjamini and Hochberg  for controlling the false 
discovery rate (FDR).83 
7.3.4 Association between microbiome composition and metabolites  
Association s between microbiome and metabolites will be explored through  correlation analysis and 
clustering analysis, focusing on the metabolites and microbial taxa that change over the study periods.  Repeated measurement regression analysis of metabolite with time -varying covariates (microbiome 
diversity or microbial genera) will be used to identify the microbial genera that are associated with 
changes of metabolites due to p -inulin treatment.  
7.3.5 Analysis of Safety  
Standard descriptive statistics will be used to summarize adverse events during the three phases (pre -
treatment, p -inulin treatment, and post -treatment)  and graphical methods including stem -and-leaf 
diagrams will be used to examine distributions of adverse events.  F requencies will be compared 
between the treatment and non -treatment phases for the total number of events, number of 
participants  experiencing events, events within body system categories (e.g., gastrointestinal system 
events), and events within severity categories.  
8 Safety and Adverse Events  
8.1 Defin itions  
Definitions are per the January 2007 Guidance on Reviewing and Reporting Unanticipated Problems Involving Risks to Participants  or Others and Adverse Events, Office on Human Research Protection 
(OHRP) Guidance. http://www.hhs.gov/ohrp/policy/advevnt guid.html  
HD Microbiome Study   22 
Version  V2.0, September 9, 2015  
 
CONFIDENTIAL  
Do not disclose or use except as authorized by the Hemodialysis Novel Therapies Consortium.  8.1.1 Adverse Event  
An adverse event (AE) is any untoward or unfavorable medical occurrence in a human study participant, 
including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or 
disease, temporally associat ed with the participant’s involvement in the research, whether or not 
considered related to the participant ’s participation in the research.  
8.1.2 Serious Adverse Event  
A serious adverse  event  (SAE ) is any AE that is:  
• fatal or results in death  
• life-threatening 
• requires or prolongs hospital stay  
• results in persistent or significant disability or incapacity  
• results in congenital anomalies or birth defects  
• an important medical event*  
*Important medical events  are those that may not be immediately life threatening, but are clearly of 
major clinical significance.  
8.1.3 Unanticipated Problems Involving Risk to Participants  or Others   
An Unanticipated Problem is any incident, experience, or outcome that meets all of the following 
criteria:  
• it is unexpected (in terms of nature, severity, or frequency) given the research procedures that 
are described in the IRB-approved research protocol and informed consent document  and the 
characteristics of the participant  population being studied;  
• it is related or possibly related to participation in the research; possibly related means that there 
is a reasonable possibility that the incident, experience or outcome may have been caused by 
the procedures involved in the research , and  
• it suggests that the research places participants  or others at a greater risk of harm (including 
physical, psychological, economic, or social harm) related to the research than was previously known or recognized.  
8.1.4 Pre- Existing Condition  
A preexisting condition is one that is present at the start of the study.  A preexisting condition will be 
recorded as an adverse event if the frequency, intensity, or the character of the condition worsens 
during the study period.  
8.2 Adverse Event Reporting  Period  
The study period during which adverse events must be tracked and reported is defined as the period 
from the initiation of study procedures to study completion.   
HD Microbiome Study   23 
Version  V2.0, September 9, 2015  
 
CONFIDENTIAL  
Do not disclose or use except as authorized by the Hemodialysis Novel Therapies Consortium.  8.2.1 Post -study Adverse Event  
All unresolved adverse events will be followed by the investigator un til the events are resolved, the 
participant  is lost to follow -up, or the adverse event is otherwise explained.  At the last scheduled visit, 
the investigator will instruct each participant  to report any subsequent event(s) that the participant , or 
the participant ’s personal physician, believes might reasonably be related to participation in this study.  
The investigator will notify the Data Coordinating Center (DCC) of any death or adverse event occurring 
at any time after a participant  has discontinued or  terminated study participation that m ay reasonably 
be related to the study.   
8.3 Recording of Adverse Events 
At each contact with the participant , the investigator or site designee will seek information on adverse 
events by specific questioning and, as appro priate,  by examination.  Information on adverse events will 
be recorded in the source document, and also on the adverse event log case report form (CRF).  All 
signs, symptoms, and abnormal diagnostic procedure results  relating to the same event will be  recorded 
under one diagnosis  name . 
8.3.1 Anticipated Adverse Events  
The following adverse events are anticipated in the hemodialysis population and are not  considered 
Unanticipated Problems .  Note that the designation as  “Anticipated” does not imply that the event is not 
an SAE  but relates to the regulatory definition of Unanticipated Problems as provided in Section 8.1.3.  
• Death  
• Coronary Ischemia including:  
o Unstable angina  
o Acute MI  
o Coronary revascularization  
• Heart failure  hospitalization or exacerbation  
• Cardiac arrest  
• Cardiac arrhythmia (ventricular or atrial)  
• Peripheral vascular revascularization  
• Amputation  
• Hypotension  
• Vomiting  
• Vascular Access Events Including:  
o Catheter exchange, removal or declotting  
o Arteriovenous graft or fistula complications  
 Clotting  
 Stenosis  
 Revascularization  
 Infection  
• Infections Including:  
o Pneumonia  
HD Microbiome Study   24 
Version  V2.0, September 9, 2015  
 
CONFIDENTIAL  
Do not disclose or use except as authorized by the Hemodialysis Novel Therapies Consortium.  o Bacteremia  
Hemodialysis v ascular access infection N on-R eportable Events  
The hemodialysis population is characterized by frequent laboratory testing and a high rate of peri-
dialytic hypotensive events requiring change in the dialysis prescription, adjustment of dry weight or change in dialysis -related medications.  Due to the u nique nature of this population, the following 
events are considered routine aspects of chronic dialysis therapy and they will not be considered to 
meet the criteria of SAE in this study except as noted:  
• Anemia —will be reported only when hemoglobin <8.0 mg/dL 
• Hyperphosphatemia -will be reported only when phosphorus >9.5 mg/dL  
• Hypocalcemia- will be reported only when serum calcium < 7.0 mg/dL  
• Hypercalcemia- will be reported only when serum calcium >11.0 mg/dL  
• Hyperparathyroidism -will be reported only when PTH>1 000 pg/mL  
• Hypotension- will be reported only when requiring emergency room visit or  hospitalization  
8.4 Reporting of Serious Adverse Events and Unanticipated Problems  
Study sites are required to report SAEs  to the DCC within 24 hours of first knowledge of the event.  To 
report such events, an SAE form will be completed by the investigator and faxed or emailed to the 
DCC.   The DCC will facilitate the timely medical review and reporting of the event and updates to  the 
NIDDK  and the  Data and Safety Monitoring Board ( DSMB ) in accordance with  DSMB -approved study 
policies  and regulatory requirements  (see Section 8.5.1 for details of the DSMB) . 
The investigator will keep a copy of th e SAE form on file at the study site.  At the time of t he initial 
report, the following information should be provided:  
 Study identifier  
 Study Center  
 Participant  number  
 A description of the event  
 Date of onset  
 Current status   Whether study treatment was discontinued  
 The reason why the event is classified as ser ious 
 Investigator assessment of the association 
between the event and study participation  
 
Within the following 7 days, the investigator will provide further information on the SAE  or the 
unanticipated problem in the form of a written narrative.   This should include a copy of the completed 
SAE form , and any other diagnostic information that will assist t he understanding of the event.  
Significant new information on ongoing serious adverse events should be provided promptly to the DCC . 
If a participant  becomes pregnant while participating in the study  it will be reported as an adverse event 
and will trigger the collection of additional d ocumentation about the pregnancy.  Pregnancy outcomes 
will be collected, including the outcome of the infant and if the pregnancy was terminated.  This 
information  will be submitted to the University of Pennsylvania IRB, and to the local site IRB as required.  
HD Microbiome Study   25 
Version  V2.0, September 9, 2015  
 
CONFIDENTIAL  
Do not disclose or use except as authorized by the Hemodialysis Novel Therapies Consortium.  SAEs that are still ongoing at the end of the study period must be followed up to determine the final 
outcome.  Any SAE  that occurs after the study period and is considered to be possibly related to the 
study treatment or study participation should be recorded and reported immediately.  
8.4.1 Investigator  Reporting  to the IRB  
Site investigators will report SAEs and Unanticipated problems to their IRB in accordance with the 
reporting requirements of the local IRB or with the Office of Human Research Protections  (OHRP) 
guidelines, whichever is sooner.  OHRP recommends that:  
1) Unanticipated problems that are serious adverse events should be reported to the IRB within 1 
week of the investigator becoming aware of the event; and   
2) Any other unanticipated problem should  be reported to the IRB within 2 weeks of the 
investigator becoming aware of the problem.  
Reporting  Process  
Unanticipated problems posing risks to participants  or others as noted above will be reported using the 
appropriate IRB- designated form or as a written report of the event (including a description of the event 
with information  regarding its fulfillment of the above criteria, follow -up/resolution and need for 
revision to consent form and/or other study documentation).  
Copies of each report and documentation of IRB notification and receipt will be maintained in the 
Clinical Center Investigator’s study file.  
Other Reportable E vents : 
• Any adverse event that would cause the sponsor to modify the protocol or informed consent 
form, or would prompt other action by the IRB to assure protection of human participants . 
• Information that indicates a change to the risks or potential benefits of the research, in terms of 
severity or frequency.  
• Breach of confidentiality  
• Change to the protocol made  without prior IRB review to eliminate apparent immediate hazard 
to a research participant.  
• Incarceration of a participant when the research was not previously approved under Subpart C and the investigator believes it is in the best interest of the participant  to remain in the study.  
• Complaint of a participant when the complaint indicates unexpected risks or the complaint cannot be resolved by the research team.  
• Protocol violation (meaning an accidental or unintentional deviation from the IRB approved 
protocol) that in the opinion of the investigator placed one or more participants at  increased 
risk, or affects the rights or welfare of participants . 
8.4.2 DCC Notif ication to  Participating Investigators  
The DCC will notify all Clinical Center principal investigators, in a written safety report, of any adverse 
event that meets the criteria of an unanticipated and related event as described in Section 8.1.3 .   
HD Microbiome Study   26 
Version  V2.0, September 9, 2015  
 
CONFIDENTIAL  
Do not disclose or use except as authorized by the Hemodialysis Novel Therapies Consortium.  8.5 Medical  Monitoring 
Each Clinical Center Principal Investigator will be responsible for oversee ing the safety of the study at 
his/her site.  This safety monitoring will include careful assessment and appropriate reporting of adverse 
events as noted above, as well as the construction and implementation of a site data and safety -
monitoring plan.  Medical  monitoring will include a regular assessment of the number and type of 
serious adverse events.  
8.5.1 Independent Data and Safety Monitoring Board (DSMB)  
The information provided in this section of the protocol is a general description of the DSMB 
responsibilities and processes.  A DSMB charter for the Hemodialysis Novel Therapies Consortium 
include s additional detail.  The NIDDK DSMB charter is provided as an attachment in Section 15.   
A DSMB has been established by the NIDDK  and provides input to the Institute.  The DSMB is comprised 
of individuals with expertise in clinical trials design and methodology,  biostatistics, clinical nephrology  
and other relevant medical specialties.  The DSMB members are not affiliated with the study and are appointed by the NIDDK.  DSMB members will be free of conflicts of interest that could be affected by 
the outcomes of the study.  During the study, DSMB members who develop real or perceived conflicts of interest that impact objectivity will disclose them to NIDDK project officers, who will arrange for 
replacement of the member, if indicated.  
The DSMB will review the protocol before  initiation of the study. After initial approval during the course 
of the study, the primary responsibilities  of the DSMB  will be to : 
• Review safety d ata and p rovide input to protect the safety of the study participants;  
• Provide input on major changes to the research protocol and plans for data and safety 
monitoring;  
• Prov ide input on the progress of the study, including periodic assessments of data qua lity and 
timeliness, participant recruitment, accrual and retention, participant risk versus benefit, performance of the study sites, and other factors that may affect study outcomes;  
• Consider factors external to the study when relevant information becomes available, such as scientific or therapeutic developments that may have an impact on the need for continuation of 
the study, safety of the participants or the ethics of the study;  
• Provide input on modification of the study protocol or possible early termination of the study 
because of attainment of stud y objectives, safety concerns,  or inadequate performance (such as 
enro llment and retention problems).  
9 Data management  
An internet -based registration system designed by the DCC will be used for all of the pilot and feasibility 
studies of the Hemodialysis Novel Therapies Consortium  in order to promote uniformity across studies. 
The central registration system will include a randomization module for each study  that will confirm 
eligibility .  Central participant registration will also allow the DCC to generate recruitment reports across  
concurrent studies.  
HD Microbiome Study   27 
Version  V2.0, September 9, 2015  
 
CONFIDENTIAL  
Do not disclose or use except as authorized by the Hemodialysis Novel Therapies Consortium.  An Oracle Clinical data management system (DMS) designed by the DCC will be used for the collection, 
storage and management of data.  Site personnel will enter data directly using Oracle Clinical Remote 
Data Capture.  Electronic case report forms (eCRFs) will incorporate range and logical edit checks, both 
within and across forms.   Data entry will be followed daily with manual and programmed checks and 
edits  for errors and omissions.  
9.1 Data  Quality  
The DCC will collaborate with the Clinical Center investigators  to establish parameters for primary and 
secondary outcomes, safety, and descriptive values.  The data management team will use a data 
validation plan, rule set specifications, and programming logic to implement data validation rules.  The 
DCC staff will interact with Clinical Center study staff to verify queried data and track all queries to 
resolution.   
9.1.1 Quality Control  Activities  
The Quality Control Committee and the DCC will develop a quality assurance and control plan that 
ensures that study data are as precise and reliable as possible.  
Manual of Procedures  (MOP) – The MOP will describe the sequence of study conduct and provide 
detailed instruction for the performance of screening, baseline, enrollment, treatment allocation and follow -up procedures.  The MOP will provide instruction in case report form (CRF) completion, use of the 
electronic DMS , and collection, documentation and  transfer of specimens and tests to central 
laboratories.  
Training and certification procedures  – The DCC will conduct a training session before the study starts to 
train and certify personnel in the performance of study procedures.  
Site visits  – Site visits will be conducted as outlined in the Study Monitoring Plan.  Findings from site 
visits will be used to resolve problems and develop corrective action plans.  
External data sources  – The DCC will monitor quality control of data received from central laboratories .   
Internal quality control procedures  – A data validation plan, rule set specifications, and programming 
logic to implement data validation rules will be implemented.  
9.1.2 Routine reports  
The DCC will develop a set of standard enrollment,  tracking, quality review, and safety monitoring 
reports.  Adverse event reports, DSMB reports and reports for statistical analysis will be developed and 
produced on an appropriate schedule.  
9.2 Data  Security  
The DMS will be designed to prevent unauthorized a ccess to study  data and to prevent data loss due to 
equipment failure or catastrophic events. The procedures to do so encompass user account management, user privilege assignment, data loss prevention (database backup), and DMS change 
management.  User acc ess will be controlled by assignment of confidential usernames and passwords. 
HD Microbiome Study   28 
Version  V2.0, September 9, 2015  
 
CONFIDENTIAL  
Do not disclose or use except as authorized by the Hemodialysis Novel Therapies Consortium.  Study data collected at the Clinical Centers will be entered into Oracle Clinical.  This DMS  uses a secure 
connection between the client browser at the Clinical Center and the we b server at the DCC.  Data 
transmitted over this connection is authenticated by the use of digital certificates and is encrypted as it 
travels the Internet to the DCC.  
Where applicable , electronic files containing data from hand held devices  and central laboratories  will 
be transferred to the DCC using secure File Transfer Protocol ( FTP) technology.  The DCC team will 
maintain a secure FTP server.  The files transmitted using this method will be encrypted during the 
exchange.  
9.2.1 Confidentiality  
Information about study participants  will be kept confidential and managed according to the 
requirements of the Health Insurance Portability and Accountability Act of 1996 (HIPAA).  Those regulations require a signed participant  authorization informing the  participant  of the following:  
• What protected health information (PHI) will be collected from participants  in this study  
• Who will have access to that information and why  
• Who will use or disclose that information  
• The rights of a research participant  to rev oke their authorization for use of their PHI.  
In the event that a participant  revokes authorization to collect or use PHI, the investigator, by 
regulation, retains the ability to use all information collected before  the revocation of participant  
authoriza tion.  For participants  that have revoked authorization to collect or use PHI, attempts should 
be made to obtain permission to collect at least vital status (i.e. that the participant  is alive) at the end 
of their scheduled study period.  
9.3 Source  Documents  
Source data is all information, original records of clinical findings, observations, or other activities in a 
research study  necessary for the reconstruction and evaluation of the study .  Source data are contained 
in source documents.  Examples of these original documents, and data records include: dialysis unit 
records, hospital records, clinical and office charts, laboratory reports , memoranda, participant  diaries 
or evaluation checklists, pharmacy dispensing records, recorded data from automated instrumen ts, 
copies or transcriptions certified after verification as being accurate and complete, microfiches, photographic negatives, microfilm or magnetic media, x -rays, participant  files, and records kept at the 
pharmacy, at the laboratories, and at medico -tech nical departments involved in the clinical trial.  
9.3.1 Case Report  Forms 
The study CRF is the primary data collection instrument for the study.  All data requested on the CRF will 
be recorded.  All missing data will be explained.  “N/D” will be used to indicate  on the CRF that a 
procedure was not done or a question was not asked  rather than leaving a space blank.   “N/A” will be 
used to indicate that an item is not applicable to the individual case.   All entries will be printed legibly in 
black ink.  If any entry  error has been made, to correct such an error, a single straight line will be drawn 
through the incorrect entry and the correct data will be entered above it.  All such changes will be 
HD Microbiome Study   29 
Version  V2.0, September 9, 2015  
 
CONFIDENTIAL  
Do not disclose or use except as authorized by the Hemodialysis Novel Therapies Consortium.  initialed and dated.  Erasing or white -out will not be used for errors.   For clarification of illegible or 
uncertain entries, the clarification will be printed above the item,  and the clarification will be initialed 
and dated.  
9.3.2 Maintaining Anonymity  of Submitted Medical Records  
Clinical site personnel w ill de -identify all medical records before sending them to the DCC by removing  
any PHI.  Upon receipt, DCC personnel will review the records to ensure that no PHI is visible.  
9.3.3 Data Sharing  
Research results will be made available to the scientific community and public in a timely manner.  The 
primary method by which data will be  shared with the scientific community will be  through peer -
reviewed publications and presentation at scientific and professional society meet ings.   In addition , data 
and results will be submitted to the NIH in the annual progress reports required under the terms and 
conditions of the funding award.  This study will also be reg istered with clinicaltrials.gov before  
initiation.  
Data from the  stud y will be submitted to the NIDDK Data Repository in accordance with the NIDDK Data 
Sharing policy.  The policy requires that data sets be transferred no later than 2 years after study 
completion or 1 year after publication of the primary results, whichever comes first.  Through the 
repository, the study data will be made available to external investigators.   
9.3.4 Records Retention  
The site investigators will retain study documents , including participant  files and Regulatory  Binders , for 
at least 5 years after the close of the study , or longer  depending on si te institutional requirements.  
10 Study Monitoring, Auditing, and Inspecting  
10.1 Study Monitoring Plan  
A monitoring plan that may include formal visits to the Clinical Centers by members of the Consortium 
(DCC, Clinical Center investigators  and study coordinators, and NIDDK representatives) will be dev eloped 
by the Consortium Executive Committee.   Clinical Center investigators will allocate adequate time for 
such monitoring activities.  The Principal I nvestiga tor will also ensure that the monitor and  other 
compliance or quality assurance reviewers are given access to study -related documents and study -
related facilities (e.g. pharmacy, diagnostic laboratory, etc.), and have  adequate space to conduct the 
monitori ng visit.  
10.2 Auditing and Inspecting 
The DCC and Clinical Center investigator s will permit study -related monitoring, audits, and inspections 
by the IRB, the NIH , government regulatory bodies, and University compliance and quality assurance 
groups of all study  related documents (e.g. source documents, regulatory documents, data collection 
instruments, study data etc.).  The DCC and Clinical Center investigators will ensure the capability for 
inspections of applicable study -related facilities (e.g. pharmacy, diagnostic laboratory, etc.).  
HD Microbiome Study   30 
Version  V2.0, September 9, 2015  
 
CONFIDENTIAL  
Do not disclose or use except as authorized by the Hemodialysis Novel Therapies Consortium.  Participation as an investigator in this study implies acceptance of potential inspection by government 
regulatory authorities and applicable institution  compliance and quality assurance offices.  
11 Ethical Considerations  
This study will be conducted according to US and international standards of Good Clinical Practice , all 
applicable government regulations and research policies and procedures  in effect at the Institutions 
where this study is implemented . 
This protocol and any amendments will be submitted to a properly constituted independent IRB, in 
agreement with local legal prescriptions, for formal approval of the study.  The decision of the IRB concerning the conduct of the study will be made in writing to the Clinical Center investigator and a copy of this decision will be provided to the DCC  befo re commencement of the study  at the site. 
All study participants  will be provide d a consent form describing the  study and pr oviding sufficient 
information  to make  an informed decision about participating in the study.  The consent form will be 
submitted with the protocol for review and approval by the IRB.  The formal consent of a participant , 
using the IRB -approved consent form, must be obtained before that participant  undergoes any study 
procedure.  The consent form must be signed by the participant  or legally acceptable surrogate, and the 
investigator-designated research professional ob taining the consent.  
12 Study Finances  
12.1 Funding Source  
This study is financed through grants from the National Institute of Diabetes and Digestive and Kidney 
Diseases of the U.S. National Institutes of Health. 
12.2 Conflict  of Interest  
All investigators will follow the conflict of interest policies of the National Institutes of Health as well as 
their home institution.  Any investigator who has a potential conflict of interest with this study (patent 
ownership, royalties, or financial gain greater than the minimum allowable by their institution, etc.) must have the conflict reviewed by a properly constituted Conflict of Interest Committee with a Committee- sanctioned conflict management plan that has been reviewed and approved by the study  
sponsor before  participation in this study . 
12.3 Participant  Stipends or Payments  
Participants  will be compensated for participat ing in the  study.  Compensation approaches will be 
determined by the Clinical Centers and approved by the local IRB.  
13 Publication Plan  
Neither the complete, nor any part of, the results of the study carried out under this protocol, nor any of 
the information provided by the Hemodialysis Novel Therapies Consortium for the purposes of 
performing the study, will be published or passed on to any third party without the consent of the 
HD Microbiome Study   31 
Version  V2.0, September 9, 2015  
 
CONFIDENTIAL  
Do not disclose or use except as authorized by the Hemodialysis Novel Therapies Consortium.  Consortium  Executive Committee and Steering Committee.  Any investigator involved with this study is 
obligated to provide the DCC  with results of all study -related testing  and all data derived from the study.  
HD Microbiome Study   32 
Version  V2.0, September 9, 2015  
 
CONFIDENTIAL  
Do not disclose or use except as authorized by the Hemodialysis Novel Therapies Consortium.  14 References  
1. Kimmel PL, Phillips TM, Simmens SJ, et al. Immunologic function and survival in hemodialysis 
patients. Kidney Int  1998;54(1):236- 244. 
2. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular 
risk and mortality in hemodialysis patients. Kidney Int  1999;55(2):648- 658. 
3. Ioannidou E, Swede H, Dongari- Bagtzoglou A. Periodontitis pr edicts elevated C -reactive protein 
levels in chronic kidney disease. J Dent Res  2011;90(12):1411- 1415.  
4. Goncalves S, Pecoits -Filho R, Perreto S, et al. Associations between renal function, volume status 
and endotoxaemia in chronic kidney disease patients . Nephrol Dial Transplant  2006;21(10):2788-
2794.   
5. Ramos LF, Shintani A, Ikizler TA, Himmelfarb J. Oxidative stress and inflammation are associated with adiposity in moderate to severe CKD. J Am Soc Nephrol  2008;19(3):593- 599. 
6. Safieh- Garabedian B, Poole S, Haddad JJ, Massaad CA, Jabbur SJ, Saade NE. The role of the 
sympathetic efferents in endotoxin- induced localized inflammatory hyperalgesia and cytokine 
upregulation. Neuropharmacology  2002;42(6):864- 872. 
7. Sterling KA, Eftekh ari P, Girndt M, Kimmel PL, Raj DS. The immunoregulatory function of vitamin 
D: implications in chronic kidney disease. Nat Rev Nephrol  2012;8(7):403- 412. 
8. Vaziri ND. CKD impairs barrier function and alters microbial flora of the intestine: a major link to 
inflammation and uremic toxicity. Curr Opin Nephrol Hypertens  2012;21(6):587- 592. 
9. Vaziri ND, Wong J, Pahl M, et al. Chronic kidney disease alters intestinal microbial flora. Kidney Int  
2013;83(2):308- 315. 
10. Raj DS, Carrero JJ, Shah VO, et al. Soluble CD14 levels, interleukin 6, and mortality among prevalent hemodialysis patients. Am Journal Kidney Dis  2009;54(6):1072- 1080.  
11. Raj DS, Shah VO, Rambod M, Kovesdy CP, Kalantar -Zadeh K. Association of soluble endotoxin 
receptor CD14 and mortality among patients undergoing hemodialysis. Am J  Kidney Dis  
2009;54(6):1062- 1071.  
12. Ramezani A, Raj DS. The gut microbiome, kidney disease, and targeted interventions. J Am Soc 
Nephrol  2014;25(4):657- 670. 
13. Backhed F, Ding H, Wang T, et al. The gut microbiota as  an environmental factor that regulates fat 
storage. Proc Natl Acad Sci USA 2004;101(44):15718- 15723.  
14. Tang WH, Wang Z, Levison BS, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med 2013;368(17):1575- 1584.  
15. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity -associated gut 
microbiome with increased capacity for energy harvest. Nature  2006;444(7122):1027- 1031.  
16. Hooper LV, Midtvedt T, Gordon JI. How host -microbial interactions shape the nutrient environment 
of the mammalian intestine. Annu Rev Nutr  2002;22:283- 307. 
17. Hill MJ. Intestinal flora and endogenous vitamin synthesis. Eur J Cancer Prev  1997;6 Suppl 1:S43-
45. 
18. Hylemon PB, Harder J. Biotransformation of monoterpenes, bile acids, and other isoprenoids in anaerobic ecosystems. FEMS Microbiol Rev  1998;22(5):475- 488. 
19. Duncan SH, Richardson AJ, Kaul P, Holmes RP, Allison MJ, Stewart CS. Oxalobacter formigenes and its potential role in human health. App Environmen Microbiol 2002;68(8):3841- 3847.  
20. Braun- Fahrlander C, Riedler J, Herz U, et al. Environmental exposure to endotoxin and its relation 
to asthma in school- age children. N Engl J Med 2002;347(12):869- 877. 
21. Simenhoff ML, Dunn SR, Zollner GP, et al. Biomodulation of the toxic and nutritional effects of small 
bowel bacterial overgrowth in end- stage kidney disease using freeze- dried Lactobacillus 
acidophilus. Miner  Electrolyte Metab 1996;22(1- 3):92- 96. 
22. Hida M, Aiba Y, Sawamura S, Suzuki N, Satoh T, Koga Y. Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of Lebenin, a lactic acid 
bacteria preparation, to uremic patients undergoing hemodialysis. Nephron. 1996;74(2):349- 355. 
23. Kang JY. The gastrointestinal tract in uremia. Dig Dis Sci  1993;38(2):257- 268. 
24. Vaziri ND, Dure -Smith B, Miller R , Mirahmadi MK. Pathology of gastrointestinal tract in chronic 
hemodialysis patients: an autopsy study of 78 cases. AmJ Gastroenterol  1985;80(8):608- 611. 
HD Microbiome Study   33 
Version  V2.0, September 9, 2015  
 
CONFIDENTIAL  
Do not disclose or use except as authorized by the Hemodialysis Novel Therapies Consortium.  25. Kalantar -Zadeh K, Kopple JD, Deepak S, Block D, Block G. Food intake characteristics of 
hemodialys is patients as obtained by food frequency questionnaire. J Ren Nutr  2002;12(1):17- 31. 
26. Hatch M, Freel RW, Vaziri ND. Intestinal excretion of oxalate in chronic renal failure. J Am Soc 
Neph rol 1994;5(6):1339- 1343.  
27. Schena FP. Management of patients with chronic kidney disease. Intern Emerg Med 2011;6 Suppl 
1:77- 83. 
28. Jakobsson HE, Jernberg C, Andersson AF, Sjolund- Karlsson M, Jansson JK, Engstrand L. Short -
term antibiotic treatment has differing long- term impacts on the human throat and gut microbiome. 
PloS One  2010;5(3):e9836.  
29. Jernberg C, Lofmark S, Edlund C, Jansson JK. Long- term impacts of antibiotic exposure on the 
human intestinal microbiota. Microbiology  2010;156(Pt 11):3216- 3223.  
30. Lefebvre HP, Ferre JP, Watson AD, et al. Small bowel motility and colonic transit are altered in 
dogs with moderate renal failure. Am J Phy siol. Regul Integr Comp Physiol  2001;281(1):R230- 238. 
31. Wu MJ, Chang CS, Cheng CH, et al. Colonic transit time in long- term dialysis patients. Am J Kidney 
Dis  2004;44(2):322- 327. 
32. Goraya N, Wesson DE. Dietary management of chronic kidney disease: protein restriction and 
beyond. Curr Opin Nephrol Hypertens 2012;21(6):635- 640. 
33. Goraya N, Wesson DE. Acid- base status and progression of chronic kidney disease. Curr Opin 
Nephrol Hypertens  2012;21(5):552- 556. 
34. Kooman JP, van der Sande FM, Leunissen KM. Role of sodium and volume in the pathogenesis of hypertension in dialysis patients. Reflections on pathophysiological mechanisms. Blood Purif  
2004;22(1):55- 59. 
35. Sato Y, Takatsu Y, Kataoka K, et al. Serial circulating concentrations of C -reactive protein, 
interleukin (IL) -4, and IL- 6 in patients with acute left heart decompensation.  Clin Cardiol 
1999;22(12):811- 813. 
36. Niebauer J, Volk HD, Kemp M, et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 1999;353(9167):1838- 1842.  
37. Werner T, Wagner SJ, Martinez I, et al. Depletion of luminal iron alters the gut microbiota and prevents Crohn's disease- like ileitis. Gut 2011;60(3):325- 333. 
38. Liguori L. Iron protein succinylate in the treatment of iron deficiency: controlled, double- blind, 
multicenter clinical trial on over 1,000 patients. Int J Clin Pharmacol Ther Toxicol  1993;31(3):103-
123. 
39. Dou L, Cerini C, Brunet P, et al. P -cresol, a uremic toxin, decreases endothelial cell response to 
inflammatory cytokines. Kidney Int  2002;62(6):1999- 2009.  
40. Cerini C, Dou L, Anfosso F, et al. P -cresol, a uremic retention solute, alters the endothelial barrier 
function in vitro. Thromb Haemost  2004;92(1):140- 150. 
41. Aronov PA, Luo FJ, Plummer NS, et al. Colonic contribution to uremic solutes. J Amer Soc Nephrol  
2011;22(9):1769- 1776.  
42. Magnusson M, Magnusson KE, Sundqvist T, Denneberg T. Impaired intestinal barrier function measured by differently sized polyethylene glycols in patients with chronic renal failure. Gut 
1991;32(7):754- 759. 
43. Wang F, Zhang P, Jiang H, Cheng S. Gut bacterial translocation contributes to microinflammation in experimental uremia. Dig Dis Sci  2012;57(11):2856- 2862.  
44. Meijers BK, Bammens B, De Moor B, Verbeke K, Vanrenterghem Y, Evenepoel P. Free p- cresol is 
associated with cardiovascular disease in hemodialysis patients. Kidney Int  2008;73(10):1174-
1180.  
45. Bammens B, Evenepoel P, Keuleers H, Verbeke K, Vanrenterghem Y. Free serum concentrations of the protein- bound retention solute p- cresol predict mortality in hemodialysis patients. Kidney Int  
2006;69(6):1081- 1087.  
46. Stoll LL, Denning GM, Weintraub NL. Potential role of endotoxin as a proinflammatory mediator of 
atherosclerosis. Arterioscl Thromb Vasc Biol 2004;24(12):2227- 2236.  
47. Wiedermann CJ, Kiechl S, Dunzendorfer S, et al. Association of endotoxemia with carotid 
atherosclerosis and cardiovascular disease: prospective results from the Bruneck Study. J  Am Coll 
Cardiol  1999;34(7):1975- 1981.  
HD Microbiome Study   34 
Version  V2.0, September 9, 2015  
 
CONFIDENTIAL  
Do not disclose or use except as authorized by the Hemodialysis Novel Therapies Consortium.  48. Pugin J, Heumann ID, Tomasz A, et al. CD14 is a pattern recognition receptor. Immunity 
1994;1(6):509- 516. 
49. Gibson GR, Beatty ER, Wang X, Cummings JH. Selective stimulation of bifidobacteria in the human 
colon by oligofructose and inulin. Gastroenterology  1995;108(4):975- 982. 
50. Martinez I, Lattimer JM, Hubach KL, et al. Gut microbiome composition is linked to whole grain-induced immunological improvements.  ISME J  2013;7(2):269- 280. 
51. Ewaschuk JB, Diaz H, Meddings L, et al. Secreted bioactive factors from Bifidobacterium infantis enhance epithelial cell barrier function. Am J Physiol  Gastrointest Liver Physiolphysiol Nov 
2008;295(5):G1025- 1034.  
52. Furrie E, Macfarlane S, Kennedy A, et al. Synbiotic therapy (Bifidobacterium longum/Synergy 1) 
initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut 2005;54(2):242- 249. 
53. Kelly D, Conway S, Aminov  R. Commensal gut bacteria: mechanisms of immune modulation. 
Trends  Immunol  2005;26(6):326- 333. 
54. Mazmanian SK, Liu CH, Tzianabos AO, Kasper DL. An immunomodulatory molecule of symbiotic 
bacteria directs maturation of the host immune system. Cell 2005;122(1):107- 118. 
55. Rakoff -Nahoum S, Paglino J, Eslami -Varzaneh F, Edberg S, Medzhitov R. Recognition of 
commensal microflora by toll -like receptors is required for intestinal homeostasis. Cell 
2004;118(2):229- 241. 
56. Cani PD, Neyrinck AM, Fava F, et  al. Selective increases of bifidobacteria in gut microflora improve 
high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. 
Diabetologia  2007;50(11):2374- 2383.  
57. Nakabayashi I, Nakamura M, Kawakami K, et al. Effects of synbiotic treatment on serum level of p-
cresol in haemodialysis patients: a preliminary study. Nephrol Dial Transplant  2011;26(3):1094-
1098.  
58. Meijers BK, De Preter V, Verbeke K, Vanrenterghem Y, Evenepoel P. p- Cresyl sulfate serum 
concentrations in haemodialysis patients are reduced by the prebiotic oligofructose -enriched inulin. 
Nephrol Dial Transplant  2010;25(1):219- 224. 
59. Roberfroid MB, Van Loo JA, Gibson GR. The bifidogenic nature of chicory inulin and its hydrolysis products. J Nutr  1998;128(1):11- 19. 
60. Roberfroid MB. Introducing inulin- type fructans. Br J Nutr. 2005;93 Suppl 1:S13- 25. 
61. Kelly G. Inulin- type prebiotics: a review. (Part 2). Altern Med Rev  2009;14(1):36- 55. 
62. Bouhnik Y, Raskine L, Simoneau G, Paineau D, Bornet F. The capacity of  short -chain fructo-
oligosaccharides to stimulate faecal bifidobacteria: a dose- response relationship study in healthy 
humans. Nutr J 2006;5:8.  
63. Carabin IG, Flamm WG. Evaluation of safety of inulin and oligofructose as dietary fiber. Regul 
Toxicol Pharmacol  1999;30(3):268- 282. 
64. Dewulf EM, Cani PD, Claus SP, et al. Insight into the prebiotic concept: lessons from an 
exploratory, double blind intervention study with inulin- type fructans in obese women. Gut 
2013;62(8):1112- 1121.  
65. Kellow NJ, Coughlan MT, Reid CM. Metabolic benefits of dietary prebiotics in human subjects: a 
systematic review of randomised controlled trials. Br.J Nutr  2013:1- 15. 
66. Gori A, Rizzardini G, Van't Land B, et al. Specific prebiotics modulate gut microbiota and immune 
activati on in HAART -naive HIV -infected adults: results of the "COPA" pilot randomized trial. 
Mucosal.Immunol  2011;4(5):554- 563. 
67. Monachese M, Cunningham -Rundles S, Diaz MA, et al. Probiotics and prebiotics to combat enteric 
infections and HIV in the developing world: a consensus report. Gut Microbes  2011;2(3):198- 207. 
68. Scaldaferri F, Gerardi V, Lopetuso LR, et al. Gut microbial flora, prebiotics, and probiotics in IBD: 
their current usage and utility. Biomed.Res.Int  2013;2013:435268.  
69. Bouhnik Y, Achour L, Paineau D, Riottot M, Attar A, Bornet F. Four -week short chain fructo-
oligosaccharides ingestion leads to increasing fecal bifidobacteria and cholesterol excretion in healthy elderly volunteers. Nutr.J  2007;6:42.  
70. Garcia -Peris P, Ve lasco C, Lozano MA, et al. Effect of a mixture of inulin and fructo- oligosaccharide 
on Lactobacillus and Bifidobacterium intestinal microbiota of patients receiving radiotherapy: a 
randomised, double- blind, placebo- controlled trial. Nutr Hosp 2012;27(6):1908- 1915.  
HD Microbiome Study   35 
Version  V2.0, September 9, 2015  
 
CONFIDENTIAL  
Do not disclose or use except as authorized by the Hemodialysis Novel Therapies Consortium.  71. Dehghan P, Gargari BP, Jafar -Abadi MA, Aliasgharzadeh A. Inulin controls inflammation and 
metabolic endotoxemia in women with type 2 diabetes mellitus: a randomized- controlled clinical 
trial. Int.J Food Sci.Nutr  2013; 65(1):117- 123. 
72. de Preter V, Vanhoutte T, Huys G, Swings J, Rutgeerts P, Verbeke K. Baseline microbiota activity 
and initial bifidobacteria counts influence responses to prebiotic dosing in healthy subjects. Aliment 
Pharmacol Ther  2008;27(6):504- 513. 
73. Schiffrin EJ, Thomas DR, Kumar VB, et al. Systemic inflammatory markers in older persons: the 
effect of oral nutritional supplementation with prebiotics. J Nutr Health Aging 2007;11(6):475- 479. 
74. Kotzampassi K, Giamarellos -Bourboulis EJ, Voudouris A, Kazamias P, Eleftheriadis E. Benefits of a 
synbiotic formula (Synbiotic 2000Forte) in critically Ill trauma patients: early results of a randomized 
controlled trial. World J Surg 2006;30(10):1848- 1855.  
75. Bouhnik Y, Raskine L, Simoneau G, et al. The capacity of nondigestible carbohydrates to stimulate 
fecal bifidobacteria in healthy humans: a double- blind, randomized, placebo- controlled, parallel-
group, dose- response relation study. Am J Clin Nutr  2004;80(6):1658- 1664.  
76. Bouhnik Y, Vahedi K, Achour L, et al. Short -chain fructo -oligosaccharide administration dose-
dependently increases fecal bifidobacteria in healthy humans. J Nutr  1999;129(1):113- 116. 
77. Meijers BK, Bammens B, De MB, Verbeke K, Vanrenterghem Y, Evenepoel P. Free p- cresol is 
associated with cardiovascular disease in hemodialysis patients. Kidney Int  2008;73(10):1174-
1180.  
78. Rao AV. Dose- response effects of inulin and oligofructose on intestinal bifidogenesis effects. J Nutr  
1999;129(7 Suppl):1442S -1445S.  
79. Briet F, Achour L, Flourie B, et al. Symptomatic response to varying levels of fructo-
oligosaccharides consumed occasionally or regularly. European J Clin Nutr  1995;49(7):501- 507. 
80. Bruhwyler J, Carreer F, Demanet E, Jacobs H. Digestive tolerance of inul in-type fructans: a double-
blind, placebo- controlled, cross -over, dose- ranging, randomized study in healthy volunteers. Int J 
Food Sci Nutr  2009;60(2):165- 175. 
81. Svedlund J, Sjodin I, Dotevall G. GSRS--a clinical rating scale for gastrointestinal symptom s in 
patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 1988;33(2):129- 134. 
82. Chen J, Bittinger K, Charlson ES, et al. Associating microbiome composition with environmental covariates using generalized UniFrac distances. Bioinfo rmatics 2012;28(16):2106 -2113.  
83. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to 
multiple t esting. J R Stat Soc Ser B- Methodol 1995;57(1):289- 300. 
84. Zhou L, Huang J, Carrol RJ.  Joine modeling of paired sparse functional data using principal components. Biometrika 2008;95:601- 619. 
85. Davidian M, Giltinan D. Some simple methods for estimating intra- individual variablity in nonlinear 
mixed effects models. Biometrics 1993;49:59- 73 
HD Microbiome Study   36 
Version  V2.0, September 9, 2015  
 
CONFIDENTIAL  
Do not disclose or use except as authorized by the Hemodialysis Novel Therapies Consortium.  15 Attachments  
 
 
        
 
         
 
        
 
HD Microbiome Study   37 
Version  V2.0, September 9, 2015  
 
CONFIDENTIAL  
Do not disclose or use except as authorized by the Hemodialysis Novel Therapies Consortium.  15.1 Study Procedure s 
 
 SCREENING  Observation with no treatment  TREATMENT PHASE WEEKS 9 -20 Observation with no treatment  
Procedure  Pre 
screening  Screening 
Visit1 Baseline  
Week 1  Weeks 
2-3 Week  
4 Weeks 
5-7 Week  
8 Week  
9 Weeks 
10-11 Week  
12 Weeks 
13-15 Week  
16 Weeks 
17-19 Week  
20 Week  
21 Weeks 
22-23 Week  
24 Weeks  
25-27 Week 
28 
Prelim inary eligibility assessment X                   
Informed consent   X                  
Confirm eligibility   X X                 
Demographic info & medical 
history   X               
   
Concomitant medications   X X  X  X   X  X  X   X  X 
Serum pregnancy   X                  
Blood specimen collection2   X X X X X X X X X X X X X X X X X 
Stool sample collection    3X 3X 3X 3X 4X 4X 3X 3X 3X 3X 3X 4X 4X 3X 3X 3X 3X 
Antibiotic use review (weekly)    X X X X X X X X X X X X X X X X X 
GI symptom assessment    X  X  X   X  X  X   X  X 
Food frequency questionnaire    X    X       X     X 
Review adverse events      X  X   X  X  X   X  X 
Follow -up visit      X  X   X  X  X   X  X 
Dispense study medication        X   X  X        
Reconcil e study medication           X  X  X      
Dose adjustment (prn)         X      
1 Screening and baseline activities can be performed at two separate visits or as one visit  
2 Hemoglobin results from the dialysis unit patient record must be reviewed before  each blood draw.  If this result is less than 9.0 g/dl, blood will  
   not be collected until  the hemoglobin value is 9.0 g/dl  or greater.  
3 Collect 1x per week  
4  Collect 2x per week  
HD Microbiome Study   38 
Version  V2.0, September 9, 2015  
 
CONFIDENTIAL  
Do not disclose or use except as authorized by the Hemodialysis Novel Therapies Consortium.  15.2 DSMB Charte r 
 
Data and Safety Monitoring Board (DSMB) Charter  
Hemo dialysis  Novel Therapies Consortium  
 
The Data and Safety Monitoring Board (DSMB) will act in an advisory capacity to the National Institute of 
Diabetes, Digestive and Kidney Diseases (NIDDK) to monitor patient safety and evaluate the efficacy of 
the interventions.  The H emodialysis  Novel Ther apies Consortium – Gut Microbiome and p -Inulin in 
Hemodialysis  study  is funded by the NIDDK.  
 DSMB RESPONSIBILITIES  
 The initial responsibility of the DSMB will be to review the study protocols, consent documents and plans for data safety monitoring, and approve the initiation of these clinical trials. After this approval, and at periodic intervals during the course of the trials, the DSMB responsibilities are to:  
• review and approve major changes in the research protocol, informed consent documents and plans for data safety and monitoring, including all proposed revisions;  
• evaluate the progress of the trial, including periodic assessments of data quality and timeliness, participant recruitment, accrual and retention, participant risk versus benefit, performance of the trial sites, and other factors that may affect study outcome;  
• consider factors external to the study when relevant information becomes available, such as scientific or therapeutic developments that may have an impact on the safety of the pa rticipants 
or the ethics of the trial;  
• protect the safety of the study participants;  
• report on the safety and progress of the trial;  
• make recommendations to the NIDDK, the Steering Committee and, if required, to the Food and Drug Administration (FDA) and the Institution Review Boards (IRBs) concerning continuation, termination or other modifications of the trial based on the observed beneficial or adverse effects of the treatment under study;  
• if appropriate, conduct interim analysis of efficacy in accordance with stopping rules which are clearly defined in advance of data analysis and have the approval of the DSMB;  
• ensure the confidentiality of the trial data and the results of monitoring;  
• assist the NIDDK by commenting on any problems related to study  conduct, enrollment, sample 
size, and/or data collection.  
 
MEMBERSHIP  
 
The DSMB will consist of at least eight members. Five participating members will constitute a quorum. The members have been appointed by the NIDDK. Members of the DSMB shall have no financial, scientific, or other conflict of interest with the studies. Collaborators or associates of the investigators in this trial are not eligible to serve on the DSMB. Written documentation attesting to absence of conflict of interest is required.  
  Dr. Paul Palevsky of University of Pittsburgh School of Medicine has been selected by the NIDDK to serve as the DSMB Chairperson for the remainder of the study. He is responsible for overseeing the meetings 
and developing the agenda in consultation with the NIDDK Program Directors, Dr. Paul Kimmel and Dr. 
John Kusek.  Dr. Kimmel  will serve as the DSMB Executive Secretary.  The Chairperson is the contact 
HD Microbiome Study   39 
Version  V2.0, September 9, 2015  
 
CONFIDENTIAL  
Do not disclose or use except as authorized by the Hemodialysis Novel Therapies Consortium.  person for the DSMB.  Other NIDDK official (s) or NIDDK appointee (s) may serve as an ex -officio member 
(s) of the DSMB.  The DCC, University of Pennsylvania, shall provide the logistical management for the 
DSMB, in coordination with NIDDK (Dr. Yining Xie, as point of contact). Whenever possible, Dr. Robert Star, Director of the Division of Kidney, Urology and Hematology of NIDDK will also attend meetings.  
 
BOARD PROCESS  
 
The DSM B will meet a minimum of once a year at the call of the Chair, with advance approval of the 
NIDDK Program Director.  An NIDDK representative will be present at every meeting.   Meetings shall be closed to the public because discussions may address confiden tial patient data. 
Meetings are attended, when appropriate, by the principal investigator and members of his/her  staff.  
Meetings may be convened as conference calls/webinars as well as in person. An emergency meeting of the DSMB may be called at any time by the Chairperson or by the NIDDK Program Director should questions of patient safety arise. The DSMB Chairperson should contact the NIDDK Program Director 
prior to convening the meeting.  
 
MEETING FORMAT  
 An appropriate format for DSMB meetings consists of open, closed and executive sessions. This format 
may be modified as needed. A brief closed and/or an executive session will usually be held before the open session.  
 
Open Session: 
 
The members of the DSMB, the NIDDK staff, the steering committee, inclu ding the study biostatistician 
will attend the open session.  Issues discussed will include the conduct and progress of the study, 
including patient recruitment, data quality, general adherence and toxicity issues, compliance with protocol, and any other l ogistical matters that may affect either the conduct or outcome of the study.  
Protocol amendments may also be presented in this session.  
 
Closed Session: 
 The closed session will be attended by voting DSMB members, representatives from the NIDDK, or its appointees, and the study biostatistician. The discussion at the closed session is completely 
confidential.  
 
Analyses of blinded outcome data are reviewed by masked intervention groups, including baseline 
characteristics, primary and secondary outcomes, adv erse events, adherence and dropouts, and 
examination of any relevant subgroups. However, the DSMB may request unmasking of the data for either safety or efficacy concerns.   
 
Executive Session:  
 The executive session will be attended by voting DSMB members, and the NIDDK Staff, or its appointees.  
 The DSMB will discuss information presented to it during the closed and open sessions and decide whether to recommend continuation or termination, protocol modification or other changes to the 
HD Microbiome Study   40 
Version  V2.0, September 9, 2015  
 
CONFIDENTIAL  
Do not disclose or use except as authorized by the Hemodialysis Novel Therapies Consortium.  conduct of the study in the Executive Session.  The DSMB can become unblinded if trends develop either 
for benefit or harm to the participants.  
 Should the DSMB decide to issue a termination recommendation, a full vote of the DSMB will be required. In the  event of a split vote, majority vote will rule and a minority report should be appended.  
Reasons for early termination may include:  
• Serious adverse effects in the entire intervention group or in a dominating subgroup; 
• Greater than expected beneficial eff ects;  
• A statistically significant difference by the end of the study is improbable; 
• Logistical or data quality problems so severe that correction is not feasible.  
 
Final Open Session (optional): 
 The final session may be attended by voting DSMB members, st eering committee members, the study 
biostatistician or other study members, and the NIDDK staff.  
 The Chairperson of the DSMB or the NIDDK Staff shall report on the recommendations of the DSMB regarding study continuation and concerns regarding the conduct  of the study.  Requests regarding data 
presentation for subsequent meetings will be made.  Scheduling of the next DSMB meeting may be discussed.  
 REPORTS  
 Interim Reports : Interim reports will be prepared by the Data Coordinating Center, located at the 
University of Pennsylvania.  The reports will be distributed to the DSMB and the NIDDK Program Director at least 7 days prior to a scheduled meeting. These interim reports are numbered and provided in sealed envelopes within an express mailing package or b y secure email as the DSMB prefers. The contents of 
the report are determined by the DSMB. Additions and other modifications to these reports may be directed by the DSMB on a one -time or continuing basis. Interim data reports generally consist of two 
parts : 
 Part 1 ( Open Session Report ) provides information on study aspects such as accrual, baseline 
characteristics, and other general information on study status.  This report is generally shared with all investigators involved with the clinical trial.  The reports contained in this section may include:  
o Comparison of Target Enrollment to Actual Enrollment by Month  
o Comparison of Target Enrollment to Actual Enrollment by Site  
o Overall Subject Status by Site, including: Subjects Screened, Enrolled, Active, Completed and Terminated  
o Demographic and Key Baseline Characteristics by Group  
o Treatment Duration for Subjects who Discontinue Therapy  
o Adverse Events/Serious Adverse Events by Site and Subject  
 Part 2 ( Closed Session Report ) may contain data on study outcomes, including safety data, including 
serious adverse events or termination.  Data will be presented by masked  treatment groups; however, 
the DSMB may request that the treatment groups be unmasked  to ensure that there are no untoward 
treatment effects. Thi s report should not be viewed by any members of the clinical trial except the 
designated study statistician.  
 
HD Microbiome Study   41 
Version  V2.0, September 9, 2015  
 
CONFIDENTIAL  
Do not disclose or use except as authorized by the Hemodialysis Novel Therapies Consortium.  Reports from the DSMB:  A formal report containing the recommendations for continuation or 
modifications of the study, prepared by the Executive Se cretary with concurrence of the DSMB, will be 
sent to the Chair of the Steering Committee and the DCC PI. This report will also contain any 
recommendations of the NIDDK in reference to the DSMB recommendations.  It is the responsibility of the DCC PI to di stribute this report to all other PIs and to assure that copies are submitted to all the IRBs 
associated with the study.  
 Each report should conclude with a recommendation to continue or to terminate the study. This recommendation should be made by formal majority vote. A termination recommendation may be made 
by the DSMB at any time by majority vote. The NIDDK is responsible for notifying the Chair of the Steering Committee of a decision to terminate the study. In the event of a split vote in favor of cont inuation, a minority report should be contained within the regular DSMB report. The report should 
not include unblinded data, discussion of the unblinded data, or any other confidential data.  
 Mailings to the DSMB: On a scheduled basis, (as agreed upon by  the DSMB) blinded safety data should 
be communicated to all DSMB members and the NIDDK Program Director. Any concerns noted by the DSMB should be brought to the attention of the NIDDK Program Director.  
 Access to Interim Data:  Access to the accumulating endpoint data should be limited to as small a group 
as possible. Limiting the access to interim data to the DSMB members relieves the investigator of the burden of deciding whether it is ethical to continue to randomize patients and helps protect the study  
from bias in patient entry and/or evaluation.  
 CONFIDENTIALITY  
 
All materials, discussions and proceedings of the DSMB are completely confidential. Members and other 
participants in DSMB meetings are expected to maintain confidentiality . 
  